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Abstract: It is well established that physically fit individuals have a reduced risk of developing CVD (cardiovascular disease) and other 
age-related chronic disorders. Regular exercise is an established therapeutic intervention with an enormous range of benefits. Chronic 
low-grade systemic inflammation may be involved in atherosclerosis, diabetes and in pathogenesis of several chronic pathological condi-
tions; recent findings confirm that physical activity induces an increase in the systemic levels of a number of cytokines and chemokines 
with anti-inflammatory properties. The possibility that regular physical exercise exerts anti-inflammation activity, being the interaction 
between contracting muscle and the other tissues and the circulating cells mediated through signals transmitted by “myokines” produced 
with muscle contractions. To date the list of myokines includes IL-6, IL-8, and IL-15. During muscle contractions are also released IL-
1receptor antagonis and sTNF-R, molecules that contribute to provide anti-inflammatory actions.  
Nevertheless discrepancies, analysis of available researches seem to confirm the efficacy of regular physical training as a non-
pharmacological therapy having target chronic low-grade inflammation. Given this, physical exercise could be considerate a useful 
weapon against local vascular and systemic inflammation in atherosclerosis. Several mechanisms explain the positive effect of chronic 
exercise, nevertheless, these mechanisms do not fully enlighten all pathways by which exercise can decrease inflammation and endothe-
lial dysfunction, and hence modulate the progression of the underlying disease progress.  
Keywords: Physical exercise, atherosclerosis, inflammation, C-reactive protein, interleukin-6.  
INTRODUCTION 
Atherosclerosis: an Inflammatory Disease 
 Since in 1999 Russell Ross published his review [1], atheroscle-
rosis has been considered an inflammatory disease and several stud-
ies have been performed on this matter. Pathophysiology of athero-
sclerosis is mainly characterized by the accumulation of lipids and 
fibrous elements in the large arteries, but this “classical” view of 
the pathophysiology of atherosclerosis is rapidly changing. The link 
between lipids and atherosclerosis dominated our thinking until the 
1970s [2]. The emerging knowledge of vascular biology led to a 
focus on growth factors and the proliferation of smooth muscle 
cells in the 1970s and 1980s [2]. Over the past decade, however, 
there has been much focus on the role of inflammation in the 
pathogenesis of atherosclerosis [3,4]. Furthermore, inflammation 
has been suggested to be a key factor in several other chronic dis-
eases such as insulin resistance [5], colorectal cancer [6], stroke [7], 
chronic obstructive pulmonary disease (COPD) [8] and Alzheimer’s 
disease [9].  
 The analysis of the relationship among atherosclerosis and in-
flammation is not the topic of this review, being widely discussed 
elsewhere in this special issue, but should be underlined that it has 
been recognized that pleiotropic cytokines are not only important 
signals in immune function, as they also represent important regula-
tors of endocrine systems, the metabolism, the coagulation system, 
and the brain function. In addition, it has been discovered recently 
that circulating levels of cytokines in vivo are affected significantly 
by contributions of cells outside the immune system such as adi-
pose tissue, skeletal muscle, and endothelial cells in healthy hu-
mans; e.g., 30% of interleukin (IL)-6 in plasma is derived from fat 
tissue [10]. The concept of regulatory adipokines has developed 
together with the discovery of fat tissue as an important endocrine 
organ, producing and secreting classical cytokines including tumor  
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necrosis factor (TNF)-, IL-6, IL-18, as well as a wide range of 
other new peptides [11]. Moreover, at the millennium, it was dem-
onstrated that working skeletal muscles produce and also release 
cytokines to the circulation [12]. Considering that skeletal muscle is 
the largest organ in the body, the perspective of this finding is revo-
lutionary, and it provides a molecular explanation about a molecu-
lar level by which we may understand how exercise mediates some 
of the health beneficial effects in relation to chronic disorders asso-
ciated with systemic low-level inflammation. 
Chronic Systemic Low-level Inflammation 
 Chronic Systemic Low-level Inflammation is defined as modest 
(2-4-fold) elevations in circulating levels of pro-inflammatory and 
anti-inflammatory cytokines, natural occurring cytokine antago-
nists, and acute-phase proteins, as well as minor increases in counts 
of neutrophils and natural killer cells [13]. Although these increases 
are far from levels observed during acute, severe infections, sys-
temic low-level inflammation is strongly associated with increasing 
age, lifestyle factors such as smoking, obesity, and dietary patterns, 
together with increased risk of CVD, COPD, cognitive decline, and 
wasting/cachexia (loss of skeletal muscle cells) [14,15]. Several 
reports investigating various markers of inflammation in different 
population groups have confirmed an association between low-
grade systemic inflammation on one hand and the metabolic syn-
drome, Type 2 diabetes, and atherosclerosis on the other [16-18]. 
Moreover, systemic low-level inflammation is a strong, consistent, 
and independent predictor of all-cause mortality and CVD-cause 
mortality in elderly populations [19]. 
 Nevertheless, in the latest years a great debate tried to address 
the issue if the inflammatory variables are causal related to athero-
sclerosis or if systemic low-grade inflammation is a spillover of the 
disctrectual process; recent evidence suggests they really may play 
a key role in the pathogenesis of CVD and other chronic diseases 
[20]. Establish the separate effects of the different cytokines and of 
the other actors of the inflammatory process in atherosclerosis is 
very hard, because of the fact that circulating levels of inflamma-
tory mediators are often strongly correlated with each other as a 
result of their tight, regulated production and, finally because in-
flammatory mediators are correlated with other risk factors in 
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chronic morbidity, including levels of fibrinogen, albumin, choles-
terol, arterial blood pressure, and body mass index (BMI), among 
others giving the mission of scientists extremely hard. 
Health Benefit of Physical Activity 
 It is well established that physically fit individuals have a re-
duced risk of developing CVD (cardiovascular disease) and other 
age-related chronic disorders [21]. Regular exercise is an estab-
lished therapeutic intervention with an enormous range of benefits, 
including protection against atherosclerosis, colon cancer, and 
breast cancer [21], ischemic heart disease [22], heart failure [23], 
Type 2 diabetes [24], and chronic obstructive pulmonary disease 
[25]. Many are the known mechanism through physical training 
exerts its beneficial efficacy: correction of the main traditional car-
diovascular risk factors, enhancement of muscular exercise toler-
ance and improvement of physical fitness, enhancement of myocar-
dial and peripheral perfusion, augmented well-being of the individ-
ual. But many others mechanisms responsible for the protective 
effects of exercise remains to date unexplained or not completely 
clear. The available data provide sure confirmation that usual exer-
cise training reduces morbidity and mortality in atherosclerotic 
patients [26-29]. 
 Given that chronic low-grade systemic inflammation may be 
involved in atherosclerosis, diabetes and in pathogenesis of several 
chronic pathological conditions [4-9] and assumed the recent find-
ing that physical activity induces an increase in the systemic levels 
of a number of cytokines and chemokines with anti-inflammatory 
properties, in this review we discuss the possibility that regular 
physical exercise exerts anti-inflammation activity, being the inter-
action between contracting muscle and the other tissues and the 
circulating cells mediated through signals transmitted by “myoki-
nes” produced with muscle contractions, and thereby protects 
against chronic medical disorders associated with low-grade sys-
temic inflammation such as atherosclerosis. We discuss also in this 
review the effects of regular exercise on established markers and 
mediators of inflammation of atherosclerosis and the impact that 
different types and intensities of exercise may have on inflamma-
tory background of atherosclerotic damage and on vascular out-
come of patients. 
PART I - INFLAMMATORY MARKERS OF ATHERO-
SCLEROTIC DISEASE 
 Atherosclerosis is widely recognized as a chronic inflammatory 
disorder that results from the interactions between modified lipo-
proteins and various components of the immune system, including 
monocyte-derived macrophages, T-lymphocytes and a variety of 
cytokines secreted by these and other cells in the artery wall [30]. 
 Many factors contribute to the development of vascular in-
flammation of atherosclerosis during several decades of progression 
of the parietal lesions. One of the main concerns the oxidation of 
the protein and lipid components of LDL (low-density lipoprotein) 
particles [30]. Elevated LDL is a well-known CVD risk factor and 
can drive the development of atherosclerosis even in the absence of 
other known risk factors. LDL is normally permeant to the arterial 
endothelium [31], but when levels are elevated it can accumulate in 
the subendothelial (intimal) space, where it becomes oxidized by 
enzymes such as myeloperoxidase, 15-LO (lipoxygenase) and 
iNOS (inducible nitric oxide synthase) [30]. Oxidized LDL (ox-
LDL), retained in the intima and associated with the extracellular 
matrix proteins is believed to be able to promote local inflamma-
tion, contributing to initiate many of the local pro-inflammatory 
effects associated to the development of atherosclerotic plaques 
[32]. The inflammation initiated by ox-LDL is mediated largely by 
the local production of pro-inflammatory cytokines in the artery 
wall. Cytochines, locally exert their pro-inflammatory effects pro-
moting endothelial cell dysfunction; facilitating influx into the arte-
rial wall of lynphocites, neutrophils monocytes; regulating macro-
phage and T-cell activation and proliferation, altering SMC (smooth 
muscle cell) phenotype; inducing apoptosis, and finally promoting 
plaque rupture and thrombosis [33-35]. 
 Atherosclerotic damage is not only characterized by a local 
inflammation, being also demonstrated a frame of systemic in-
flammation. Probably systemic inflammation is not expression of 
vascular damage, or a simple marker of local pathology, but a 
pathogenetic element able to contribute to the systemic develop-
ment of atherosclerosis [4,5].  
 Inflammatory mechanism plays a central role in mediating all 
phases of atherosclerosis, from initial recruitment of circulating 
leucocytes to the arterial wall to eventual rupture of unstable 
plaque. Systemic inflammation in atherosclerosis, such as in several 
conditions in which is needed a response to a infection or to a tissue 
injury, involves hepatic production of proteins, called “acute-phase 
proteins”, such as CRP. Their circulating levels are currently used 
in order to assess entity of inflammatory response and, con-
secuently, severity of injury. The main cytochines involved in this 
inflammatory cascade are: TNF-, IL-1, IL-6, IL-1 receptor an-
tagonist (IL-1ra), and soluble TNF- receptors (sTNFR). IL-1ra 
inhibits IL-1 signal transduction and sTNF-R represents the natu-
rally occurring inhibitors of TNF- [36]. 
Chronic Low-grade Systemic Inflammation in Atherosclerosis 
 In response to an acute infection or trauma, the cytokines and 
cytokine inhibitors may increase severalfold and decrease when the 
infection or trauma is healed. Far from this, what we observe in 
association to atherosclerotic disease is a “chronic low-grade sys-
temic inflammation”. Chronic low-grade systemic inflammation, as 
defined before [13], accompanies aging, lifestyle factor such as 
smoking, obesity and dietary patterns as well as some chronic 
medical disorders increased risk of cardiovascular disease, type 2 
diabetes cognitive decline, and wasting/ cachexia (loss of skeletal 
muscle cells) more common in the last part of life [37-39]. During 
aging, increased plasma levels of sTNF-R [40], TNF-, IL-6, IL-
1ra and CRP [41] have been demonstrated. These cytokines work in 
a network, and their levels are found to intercorrelate, e.g., plasma 
levels of TNF- were positively correlated with IL-6, sTNF-R, and 
CRP in centenarians [38]. However, although a linear relationship 
was found for TNF- and IL-6, high levels of TNF-, but not IL-6, 
were associated with dementia and atherosclerosis [40,42]. In-
creased levels of both TNF- and IL-6 have been observed in obese 
individuals, in smokers, and in patients with Type 2 diabetes melli-
tus [43], Moreover, systemic low-grade inflammation is a strong, 
consistent, and independent predictor of all-cause mortality and 
CVD-cause mortality in elderly populations [44]. Furthermore, 
plasma concentrations of IL-6 and TNF- have been shown to pre-
dict the risk of myocardial infarction in several studies [45], and it 
was shown that the CRP level is a stronger predictor of cardiovas-
cular events than the low-density lipoprotein cholesterol level and 
that CRP adds prognostic information to that conveyed by the 
Framingham risk score [46]. 
 Presence of a state of chronic low-grade systemic inflammation 
in atherosclerotic patient is confirmed by finding of persistence 
elevation of numerous inflammatory variables, including the cyto-
kines TNF-, IL-6, IL-1, IL-2, IL-7, IL-8, IL-10, IL-18, IL-1ra, 
sTNF-R, and other related to acute phase response such as CRP, P-
selectin, soluble intercellular adhesion molecule-1 (ICAM-1), 
sCD40L (solubleCD40 ligand) and M-CSF (macrophage colony-
stimulating factor) [42]. Despite the fact that serum levels of this 
inflammation-related substances are much smaller than those seen 
in acute infection, this pattern suggest a clear involvment of in-
flammation in atherosclerosis. Determining whether they are a 
cause or a consequence of atherosclerosis remains a challenge like 
identify the contribution that individual cytokines and other in-
flammatory variables make to the development of atherosclerosis. 
This latest point is really difficult to ascertain due to the interactions 
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and redundancy between the numerous pro- and anti-inflammatory 
cytokines that define chronic inflammation. Furthermore, most 
secreted cytokines are rapidly cleared by surrounding cells or inac-
tivated by soluble inhibitors, thus measuring their circulating levels 
does not necessarily reflect their biological activity in tissues. 
 Finally, cytokines serum levels changes and could related to 
several genetic polymorphisms. Single Nuclear Polymorfisms 
(SNPs) of several cytokines genes have been demonstrated, and 
their biological action and clinical significance is actually under 
evaluation by several groups. Regarding the matter of the present 
review, polymorphisms of Il-6 and TNF- genes are the more rele-
vant. IL-6 is largely regulated at the level of expression, because of 
the rapid plasma clearance of this cytokine. Four polymorphisms 
exist in the IL-6 promoter, although most population-based studies 
focus on the G-174-C, where the C allele shows lower IL-6 expres-
sion than the G allele [47]. The G-174-C genotype is a disease “risk 
genotype” associated with cardiovascular disease and all-cause 
mortality in old humans, as well as insulin resistance and low en-
ergy expenditure [48]. Compared with the G-308G genotype, the -
308A allele of the TNF- gene has been shown to increase tran-
scription twofold and, therefore, TNF- concentration [49]. Sub-
jects with risk genotypes for both TNF- (AA) and IL-6 (CC) have 
the highest incidence of diabetes [50], favouring the theory that 
high levels of TNF- and low production of IL-6 are determining 
factors in the metabolic syndrome.  
 Given that TNF- mainly works locally, TNF- transcription 
may not always be reflected in enhanced systemic levels of TNF-. 
Rather, TNF- could be hypothesized to stimulate IL-6 production 
and consequently IL-1ra and CRP [51]. 
 For all these and also other reasons, as we can see as follows, 
the mechanisms by which inflammatory cytokines affect athero-
genesis are still poorly understood. Although in many studies, the 
effects of absence of increased levels of inflammatory cytokines on 
atherosclerosis were investigated, the exact inflammatory pathways 
are still unclear. 
 A thorough examination of the role of each of these cytokines 
in atherosclerosis is beyond the scope of this review, but a brief 
analysis of the main pro-inflammatory and anti-inflammatory cyto-
kines related to promotion or control of atherosclerosis appears 
useful. Thereby, in the following part we will try to summarize the 
main characteristics of the cytokines and of the acute phase proteins 
involved in the acute and chronic systemic response to exercise. 
 Cytokines represent a model on a molecular level, by which we 
can explain some of the interconnection amongst markers of in-
flammation, coagulation/fibrinolysis, glucose metabolism, lipid 
metabolism, the renin-angiotensin system, the hypothalamic-
pituitary axis, and others associated with systemic low-level in-
flammation in atherosclerosis, and by analysing the variations of 
which we try to explain the anti-inflammatory effect of exercise 
therapy.  
Tumor Necrosis Factor-  (TNF-) 
 TNF- is multifunctional, and one of the most important pro-
inflammatory and immune modulatory cytokines [52]. TNF- me-
diates mainly local inflammatory responses, the systemic acute-
phase response and is thought to play a central role in the develop-
ment of CVD, Type 2 diabetes and the metabolic syndrome [53]. 
Nevertheless elevated levels of TNF- protein is not always de-
tected in serum patients during systemic low-grade inflammation, 
Bruunsgaard [53] hypothesize that local (vascular, in case of athe-
rosclerosis) production of TNF- may stimulate production of IL-6 
and subsequent mediators in the inflammatory cascade; in this 
view, increases in IL-6, IL-8, C reactive protein (CRP), IL-1Ra, 
sTNFRs, IL-10, and inflammatory cells, among others, would re-
flect on-going TNF- production, and then systemic biomarkers of 
low-grade inflammation found in atherosclerotic patient may repre-
sent a response to or a spillover from local vascular inflammation 
TNF- mediated second-affecting the function in other organs and 
tissues. Probably is not completely correct to point to TNF- as the 
agent solely responsible in inflammatory disorders (as Bruunsgaard 
herself affirms later in her review), however, In terms of CVD, 
elevated circulating levels of TNF- predict risk of myocardial 
infarction (MI) [45], the severity of PAD (peripheral arterial dis-
ease) [40] and the extent of carotid artery atherosclerosis in healthy 
middle-aged men [54]. TNF-  is prevalent in atherosclerotic le-
sions [55] and induces the expression of adhesion molecules such 
as ICAM-1 (intracellular adhesion molecule-1) and E-selectin [56]. 
TNF- as well as IL-1 also promote low shearstress-induced neoin-
timal hyperplasia [57], a hallmark feature of atherosclerosis and 
finally it induces endothelial dysfunction [58]. Therefore, it should 
have a major role in atherogenesis. Surprisingly, no effect was 
found in the first article studying atherogenesis in a mouse model 
deficient for TNF- [59]. Although the experimental conditions 
weren’t optimal to evaluate atherosclerosis progression, results of 
this study seemed to reveal that such an important cytokine as TNF-
 is not absolutely crucial for the development of atherosclerosis. 
Later studies do not confirm these data showing that absence of 
TNF in apoE
-/-
 mice can reduce atherosclerosis [60]. These and 
other similar studies, indicate that the analysis of the signalling 
pathways of TNF-, could partially explain the differences ob-
served in biologic effect, infact signalling through the TNF-p55 
axis (an element of the NF-B system of nuclear transcription fac-
tors) may protect against or enhance atherogenesis, maybe depend-
ing on the genetic background of the mouse strain used. It is clear 
that TNF- signalling is not an obvious pro-atherosclerotic path-
way, but the exact mechanisms remain to be elucidated [61]. 
Interleukin-1 (IL-1) 
 IL-1 is also a proinflammatory cytokine and has been studied 
in atherosclerosis using either IL-1- deficient mice or mice lacking 
the IL-1 receptor. Absence of IL-1 in apoE-/- mice was shown to 
reduce atherosclerosis by 30% [62]. This effect was accompanied 
by decreased expression of one of the major adhesion molecules in 
atherosclerosis, VCAM-1, and chemokine MCP-1. In line with 
these data, absence of IL-1 receptor was shown recently to have 
strong reducing effects on atherosclerosis development in apoE 
+/-
 
mice [63]. It should be noted that both TNF- and IL-1 are regu-
lated by NF-B, but they are also activators of the NF-B pathway. 
Hereby, these cytokines may affect atherosclerosis by regulating 
many other NF-B dependent genes and amplify the inflammatory 
response [61]. 
Interleukin-6 (IL-6) 
 IL-6 is found primarily in the circulation, secreted by numerous 
cell types, including activated macrophages and lymphocytes, in 
response to IL-1 and TNF-. In line with other cytokines, IL-6 is 
traditionally classified as pro-inflammatory based on the fact that 
serum levels increase in response to sepsis [64], it stimulates the 
production of pro-inflammatory cytokines from monocytes and 
macrophages, and up-regulates CRP production by the liver [65]. 
There is strong evidence that IL-6 serum concentration increases 
with age and in 1993, William Ershler, in his article “IL-6: A Cyto-
kine for Gerontologists,” indicated IL-6 as one of the main signal-
ing pathways implicated in aging and chronic morbidity [66]. Many 
studies report that IL-6 plasma levels are increased in patients with 
unstable angina compared with those with stable angina or healthy 
subjects and that it could be useful as a prognostic marker of CVD 
outcome [67], increases the risk of future MI (myocardial infarc-
tion) [45] and has been linked to all-cause and CVD mortality [68]. 
IL-6 also has been hypothesized to promote atherosclerosis directly 
by enhancing endothelial expression of chemokines and adhesion 
molecules, increasing endothelial dysfunction and promoting a 
procoagulant state [69]. 
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 Studying IL-6 role in atherogenesis in IL-6 deficent mice El-
hage et al. [70] surprisingly showed how early lesion formation was 
not affected by the absence of IL-6. In contrast, when atherosclero-
sis was examined at 1 year of age, the atherosclerotic lesions were 
larger in the apoE
-/-
 IL-6 - deficient mice compared with controls, 
making IL-6 an antiatherogenic factor. Interestingly, Xing et al. 
[71] showed that IL-6 -deficient mice showed increased induction 
of proinflammatory cytokines in 2 models of local and systemic 
endotoxic shock. These observations seem to indicate that IL-6 can 
function as an anti-inflammatory cytokine required for controlling 
inflammation. Huber et al. [72] showed that administration of re-
combinant IL-6 aggravates atherosclerosis, but it is not clear 
whether this is a direct result of IL-6 or merely a reflection of the 
proatherogenic effects of systemic inflammation that might be in-
duced by IL-6. This is a problem also encountered in similar studies 
in which proinflammatory substances are administered systemi-
cally, making the direct effects on atherosclerosis difficult to inter-
pret. Supposed anti-inflammatory actions of IL-6 include inhibition 
of the production of TNF- in response to pro-inflammatory stim-
uli, such as endotoxin or lipopolysaccaride (LPS) [73], and releas-
ing of sTNFRs (soluble TNF- receptors) [51], indicating that cir-
culating IL-6 is involved in the regulation of TNF- levels. IL-6 
also stimulates the production of the anti-inflammatory cytokines 
IL-1ra (IL-1 receptor antagonist) and IL-10 [51]. In vivo studies 
appear to support an anti-inflammatory role for IL-6; deficiency in 
IL-6 has been shown to promote atherosclerosis in both C57/Bl6 
[74] and ApoE (apolipoprotein E)-deficient (ApoE/) mice [75] 
and had no effect on atherosclerosis in LDLr (LDL-receptor)-
deficient (LDLr/) mice [76]. Perhaps due to these apparent pro- 
and anti-inflammatory activities, the role of IL-6 in atherosclerosis 
and other inflammatory disorders, such as Type 2 diabetes [51] is 
controversial, being hypothesized that chronically elevated IL-6 is 
simply a marker for ongoing TNF- production during low-grade 
inflammation and may not contribute directly to the pathogenesis of 
inflammatory diseases [51,53]. With regard to patients with low-
grade chronic inflammation, as seen, e.g., in patients with CVD or 
type 2 diabetes, to date there are no published data that allow us to 
evaluate the direct metabolic effects (pro-inflammatory or anti-
inflammatory) of modest, but chronic, elevated levels of IL-6 corre-
sponding to the levels seen in these patients. However, blocking IL-
6 in clinical trials with patients with rheumatoid arthritis, a patho-
logic condition characterized by highly elevated chronic levels of 
IL-6, in which this cytokine play a clear pathogenetic role as dem-
onstrated by the fact that blocking IL-6 has beneficial effects on 
arthritis, leads to enhanced cholesterol and plasma glucose levels, 
indicating that functional lack of IL-6 may lead to insulin resistance 
and an atherogenic lipid profile [77]. These clinical findings are in 
accordance with the finding that IL-6 knockout mice develop late-
onset obesity and impaired glucose tolerance [78]. Subjects with 
risk genotypes for both TNF- (AA; A shows increased TNF tran-
scription) and IL-6 (CC; C shows decreased transcription) have the 
highest incidence of diabetes [79], favouring the theory that high 
levels of TNF- and low production of IL-6 are determining factors 
in the metabolic syndrome [80]. 
 Given the different biological profiles of TNF- and IL-6 and 
given that TNF- may trigger IL-6 release, one current theory is 
that adipose tissue-derived TNF- is actually the “driver” behind 
the metabolic syndrome and that increased systemic levels of IL-6 
reflect locally produced TNF- [51]. Accordingly, elevated levels 
of IL-6 might represent a “defense” mechanism against proinflam-
matory actions caused by TNF. An alternative hypothesis is that 
increased IL-6 production represents a compensatory mechanism, 
whereby insulin-resistant individuals or individuals at risk of devel-
oping insulin resistance stimulate an alternative mechanism with 
regard to maintaining glucose homeostasis. Finally, chronically 
elevated IL-6 levels may simply reflect a feedback mechanism due 
to impaired IL-6 signaling. It is, however, not known if “IL-6 resis-
tance” exists as a phenomenon in line with the fact that a chroni-
cally elevated level of insulin or leptin most often reflects insulin 
resistance or leptin resistance, respectively. 
C-Reactive Protein (CRP) 
 CRP is an acute phase protein, synthesized by heapatocytes, 
first described in 1930 by Tillet and Frances who identified a sub-
stance in the sera of patients acutely infected with pneumococcal 
pneumonia that formed a precipitate when combined with polysac-
charide C of Streptococcus pneumonia [81]. Liver secretion of 
CRP, follows the acute-phase protein’s response, being secreted in 
response to stimulation by several cytokines, particularly IL-6, Il-1, 
TNF-. Like many acute phase protein, CRP is normally present in 
trace levels in serum but increases rapidly and dramatically in re-
sponse to a variety of infectious or inflammatory conditions. How-
ever, recent data show that arterial tissue can produce CRP as well 
as complement proteins [82]. 
 The exact function of CRP is largely unknown. But two func-
tional properties of CRP including the ability to activate comple-
ment through the classic complement pathway, and the ability to 
modulate the function of phagocytic cells have been demonstrated.  
 Levels of CRP have been found to predict future risk among 
patients with stable and unstable angina, in the chronic phase of 
myocardial infarction, and among patients undergoing revasculari-
zation procedures [82,83], prompting some to suggest it should be 
measured as a routine clinical risk assessment test, having relevant 
prognostic value in subjects with chronic heart disease (CHD) and 
with acute coronary syndromes (ACS) [35]. Furthermore, risk 
stratification of acute cardiac patients using CRP in addition to 
cardiac troponins showed how high CRP levels at hospital admis-
sion were associated with an increased incidence of recurrent an-
gina, coronary revascularization, myocardial infarction, and cardio-
vascular death, indicating a bad outcome [84], a bad response to 
conventional therapy [85], and activation of pro-inflammatory and 
pro-atherosclerotic nuclear factor NF-B [86]. An important contri-
bution to understanding the meaning of CRP high levels in ACS has 
been provided also from Liuzzo et al., showing that patients with 
coronary vasospasm have persistently normal CRP levels, despite 
frequent episodes of ST-segment elevation [87], suggesting that the 
rise in CRP may be secondary to an underlying proinflammatory 
state, rather than due to myocardial necrosis. 
 Furthermore, baseline levels of CRP are a strong independent 
predictor of risk of future myocardial infarction, stroke, peripheral 
vascular disease, and vascular death among healthy individuals 
including man and women without known vascular disease by sev-
eral investigators [88,89]. 
 Monitoring of CRP levels has also increasing importance in 
appearing healthy subjects. Data in support of a role for CRP for 
cardiovascular risk prediction among apparently healthy individuals 
are robust and remarkably consistent across several European and 
US cohort. Several prospective studies, in the last years, have con-
sistently shown that CRP is a powerful predictor of future first 
coronary event in apparently healthy men and women. Findings 
from Multiple Risk Factors Interventional Trail (MRFIT) demon-
strated a direct positive association between CRP and coronary 
heart disease mortality in apparently healthy men followed over a 
17-year period (RR: 2.8; 95% CI, 1.4-5.4) [90,91]. In the analysis 
provided by Blake and Ridker, CRP was the single most powerful 
predicator of cardiovascular risk in all of the inflammatory and lipid 
markers. In this multivariate analysis, matched for age and smoking 
and adjusted for other cardiovascular risk factors, the authors found 
that only CRP and total cholesterol/high-density cholesterol 
(TC/HDL-C) ratio were independent predictors of future cardiovas-
cular risk [82].  
 Real meaning of CRP increase in atherosclerotic patients is still 
hard to elucidate; CRP has been considerate a spillover of the in-
flammation related to the extent and severity of atherosclerosis or 
4330    Current Pharmaceutical Design, 2012, Vol. 18, No. 28 Pinto et al. 
may reflects the amount and activity of circulating proinflammatory 
cytokines, such as TNF-, IL-1, and IL-6. But, in addition to being 
a marker of inflammation associated with atherosclerosis, some 
evidence suggests that CRP may also be a causal risk factor. Over 
the last several years, increasing evidence suggests CRP may con-
tribute directly to the proinflammatory state, indicating that CRP 
may play a direct role in vascular injury process. Several reports 
demonstrated that CRP has been localized directly within atheroma-
tous plaque where it precedes and mediates monocyte recruitment. 
So, CRP could be implicated in all phases of atherosclerosis, from 
the initial recruitment of inflammatory cells into the arterial wall to 
plaque rupture [14].  
 Direct atherosclerotic effects of CRP are related to a local effect 
into the arterial wall, colocalizing with the terminal complement 
complex and foam cells. CRP upregulates the expression of adhe-
sion molecules, and mediate proinflammatory factor induction in 
several kinds of cells in artery wall as well as circulating monocytes 
[92]. It increases opsonization of LDL and mediates the uptake of 
LDL into the macrophages, which then become foam cells. It exerts 
particularly important effects on endothelial function by inducing 
endothelial cell expression of adhesion molecules, such as ICAM-1, 
VCAM-1 (vascular cell adhesion molecule-1) and P-selectin [93] 
inhibiting the expression and activity of eNOS (endothelial nitric 
oxide synthase) [34] and reducing prostacyclin release [94]. CRP 
also induces monocyte recruitment by up-regulating endothelial cell 
expression of MCP-1 (monocyte chemoattractant protein-1) [95] 
and induces monocyte chemotaxis by upregulating monocyte ex-
pression of the MCP-1 receptor CCR-2 (CC chemokine receptor-2) 
[96]. Together, these factors promote the recruitment, binding and 
uptake of inflammatory cells, such as macrophages and T-cells, into 
the artery wall. It has been shown to bind and opsonize LDLs in the 
artery wall, enhancing their uptake by macrophages [97], and acti-
vates the complement pathway [98], leading to the production of 
proinflammatory cytokines by vascular cells. CRP also promotes 
plaque instability by inducing endothelial expression of MMP (ma-
trix metalloproteinase)-1 and MMP-10 [99], and promotes throm-
bosis by inducing the expression of PAI-1 (plasminogen activator 
inhibitor-1) [100]. 
 Once considered just a marker of inflammation, this evidence 
indicates that CRP may be directly involved in the development and 
progression of atherosclerosis. However, some recent reports sug-
gest that many of the inflammatory in vitro effects attributed to 
CRP may have been artifacts caused by the presence of contami-
nants in the CRP preparation used in the experiments [42]. Fur-
thermore, the overexpression of CRP in ApoE/ mice had either 
no effect [101] or produced only a modest increase [102] in athero-
sclerosis, and one report even indicates some protective effects of 
CRP on atherogenesis in mice [103]. As a result, there is consider-
able controversy in the literature as to whether CRP is directly in-
volved in the development of atherosclerosis and its complications. 
More research will be needed clarify these issues. 
Interleukin-10 (IL-10) 
 IL-10 is one of the main cytokines having a biological anti-
inflammatory effect. Circulating levels of Il-10 increases in the 
circulation after exercise, contributing to mediate the anti-
inflammatory effects of exercise. The concept that IL-10 acts as an 
anti-inflammatory molecule was suggested primarily by studies 
showing inhibition of the synthesis of a large spectrum of pro-
inflammatory cytokines by different cells, particularly of the mono-
cytic lineage. Thus IL-10 inhibits the production of IL-1, IL-1, 
and TNF- as well as the production of chemokines, including IL-8 
and macrophage inflammatory protein- from LPS-activated hu-
man monocytes [104,105]. These cytokines and chemokines play a 
critical role in the activation of granulocytes, monocytes/macro-
phages, natural killer cells, and T and B cells and in their recruit-
ment to the sites of inflammation. Taken together, these observa-
tions suggested that IL-10 plays an important role in orchestrating 
the inflammatory reaction involving macrophage/monocyte activa-
tion in particular. 
 IL-10 also prevents cytokine synthesis by posttranscriptional 
mechanisms, as shown in human macrophages where the inhibition 
of IL-6, IL-1, and TNF- release induced by LPS is a direct con-
sequence of mRNA degradation of their corresponding genes [106]. 
Interleukin-1 receptor antagonist (IL-1ra) 
 Main biological role provided by IL-1ra is to inhibit signaling 
transduction through the IL-1 receptor complex [107]. The IL-1ra is 
a member of the IL-1 family that binds to IL-1 receptors but does 
not induce any intracellular response. Studies have demonstrated 
that IL-1ra is also an acute phase protein [108] because both cul-
tured human hepatocytes and the human hepatoma cell line HepG2 
produce IL-1ra in response to stimulation with IL-6, confirming the 
biologic relation between the two molecules as seen during acute 
physical exercise. 
Fibrinogen 
 Several large-scale epidemiologic studies demonstrate that 
baseline fibrinogen concentrations predict future risk of myocardial 
infarction and stroke [109,111]. 
 When compared head-to-head with CRP, fibrinogen seems a 
less potent predictor of cardiovascular events [112]. Illustrating the 
importance of detection methodology, when fibrinogen is measured 
with a reliable and high-quality immunoassay, there is a significant 
association between higher concentrations of fibrinogen and CRP, 
alone and in combination, and incident cardiovascular disease in 
apparently healthy women over a 10-year follow-up period [113].  
PART II - EFFECT OF A SINGLE BOUT OF EXERCISE ON 
INFLAMMATORY MARKERS OF ATHEROSCLEROSIS 
 As underlined in the introduction, regular physical activity of-
fers protection not only against several chronic cardiovascular 
metabolic and degenerative disease such as coronary heart disease 
[22], chronic heart failure [23], type 2 diabetes, [24], colorectal 
cancer and breast cancer [21], COPD [25], age-related cognitive 
decline [114,115], and dramatically reduces all-cause mortality 
[116], but it is also effective against different mechanisms involved 
in the low-grade inflammation that may be found both in several of 
the pathologic conditions cited before, but also in the appearing 
healthy individual. In a great part of this chronic diseases regular 
physical exercise provide effective protection in primary prevention 
and could be used as a therapeutic option to modify natural history 
in secondary prevention.  
 Several of these benefits seen after regular physical exercise are 
mediated by the metabolic changes induced by training. Infact, 
exercise training involves multiple metabolic adaptations including 
increased preexercise skeletal muscle glycogen content, enhanced 
activity of key enzymes involved in the -oxidation [117], in-
creased sensitivity of adipose tissue to epinephrine-stimulated 
lipolysis [118], and increased oxidation of intramuscular triglyc-
erides [119], whereby the capacity to oxidize fat is increased [120]. 
As a consequence, the trained skeletal muscle is less dependent on 
plasma glucose and muscle glycogen as substrate during exercise 
[121]. 
 An increasing number of papers in the last decade have docu-
mented that self-reported physical activity or physical performance 
is correlated inversely with systemic low-grade inflammation [122-
132] clearly demonstrated by the analysis of circulating inflamma-
tory parameters, although the lack of an association has also been 
reported [133], especially when adjusting for other factors in multi-
variate analyses [134,135]. 
 In the InCHIANTI study [122], a prospective population-based 
study of older people, aimed at identifying risk factors for late-life 
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disability, that consisted of 1020 participants aged 65 years and 
older living in the Chianti area of Italy, inflammation, measured as 
high levels of IL-6, CRP, and IL-1RA, was significantly associated 
with poor physical performance and muscle strength in older per-
sons. In the ATTICA Study [123], a high self-reported degree of 
physical activity is associated with attenuated circulating levels of 
TNF-, IL-6, CRP, and SAA compared with those devoted to a 
sedentary lifestyle, independently of gender, age, smoking habits, 
BMI, total cholesterol, blood glucose, and blood pressure. Addi-
tionally, a similar association is observed in the same population 
when taken in account a subgroup with the metabolic syndrome and 
within a subgroup without [124]. Thus, a high level of physical 
activity is apparently associated with reduced levels of peripheral 
inflammatory mediators in the range of 20-60% compared with a 
sedentary lifestyle, although different degrees of reduction of in-
flammatory markers may be found in relation to exercise type, du-
ration and intensity [127]. 
 These correlation data do, however, not necessarily provide any 
information with regard to a possible causal relationship. However, 
several studies performed both in healthy and in unhealthy people, 
thus in presence of pathologic condition affecting the physiologic 
inflammatory asset, have reported that controlled exercise interven-
tion programs reduce systemic low-grade inflammation in patients 
with coronary heart disease [136], peripheral artery disease [137], 
chronic heart failure [138] and in healthy, young adults [139]. A 
failure of a positive effect has been reported in old nursing home 
patients [140] and in obese elderly [141]. 
 Nevertheless the great part of available data confirm how 
physical fitness is linked to low systemic low-grade inflammation, 
possible explanation of the discrepancies observed between self-
reported physical activity and systemic inflammatory markers in the 
various trial that tried to address this issue might be due to different 
experimental conditions: a large interpersonal variability in periph-
eral inflammatory markers together with a considerable coefficient 
of variability in high sensitivity cytokine essays make difficult to 
standardize cut off of the variables analyzed (healthy adult male vs 
healthy adult female vs older, etc etc). Finally, the effect of physical 
activity is likely differentiated in disorders associated with systemic 
low-level inflammation. It is probably easier to revert endothelial 
dysfunction, insulin resistance, and dyslipidaemia in CVD than 
cachexia in a terminal state. In this regard, it is possible that there is 
a threshold beyond which systemic low-level inflammation repre-
sents an irreversible state; e.g., among patients with chronic heart 
failure, exercise training reduces plasma levels of TNF- signifi-
cantly among survivors but not among nonsurvivors [142].  
 Nevertheless the discrepancies observed in the available data, 
that will be deeper analyzed in the latter part of this review and the 
lack of appropriated studies in a so relevant matter like the relation-
ship between physical exercise and inflammation, certainly, the 
demonstration that skeletal muscle during contraction prodeces and 
then releases in the circulation several myokines, open a new fron-
tier in research the relationship between myokines and metabolism 
both in physiologic and in pathologic conditions. Because systemic 
markers of inflammation are elevated in CVD and other chronic 
diseases, modifying their levels through exercise may have thera-
peutic potential; in this point of view it is essential to assess how 
the systemic low-grade inflammation balance associated to CVD 
conditions is modified by muscular-related cytokines released after 
chronic training.  
Acute Changes of Systemic Inflammatory Markers During and 
After Exercise 
 For most of the last century, researchers sought a link between 
muscle contraction and humoral changes in the form of an “exercise 
factor,” which could be released from skeletal muscle during con-
traction and mediate some of the exercise-induced metabolic 
changes in other organs such as the liver and the adipose tissue. In 
the latest years, with the discovery that cytokines or other peptides 
(classified as “myokines”) produced, expressed, and released by 
muscle fibers could exert either paracrine or endocrine effects a 
possible link between skeletal muscle contractile activity and im-
mune changes was established (see Fig. (1)). 
 So, muscle contraction during exercise results in a systemic 
cytokine cascade, considerable changing the immune system activ-
ity. 
 In the year 2000, it became clear that contracting human skele-
tal muscle releases significant amounts of IL-6 into the circulation 
during prolonged single-limb exercise [143]. An accompanying 
editorial to this publication pointed to the possibility that muscle-
derived IL-6 could have metabolic roles: “It is an intriguing possi-
bility that the IL-6 response may be a signal indicating that muscle 
glycogen stores are reaching critically low levels and that the active 
muscles’ reliance on blood glucose as a source of energy is on the 
increase” [144]. The latter statement was soon supported by ex-
perimental studies [145,146], and a number of studies highlighted 
the fact that muscle-derived IL-6 is an important player in metabo-
lism [51, 147-149].  
 The identification of skeletal muscle as a cytokine-producing 
organ soon led to the discovery that muscle-derived cytokines could 
account not only for exercise- associated immune changes, but that 
these muscle-derived cytokines played a role in mediating the exer-
cise associated metabolic changes, as well as the metabolic changes 
following training adaptation. It appears that skeletal muscle has the 
capacity to express several myokines. To date the list includes IL-6, 
IL-8, and IL-15 [148]. Contractile activity plays a role in regulating 
the expression of many of these cytokines in skeletal muscle [148].  
 IL-6 is the first cytokine present in the circulation during exer-
cise; the appearance of IL-6 in the circulation is by far the most 
marked and its appearance precedes that of the other cytokines 
[149]. The level of circulating IL-6 increases rapidly in an exponen-
tial fashion (up to 100-fold) in response to acute exercise and de-
clines in the postexercise period [12,150]. IL-6 levels elevation is 
followed by an increase of circulating levels of other well-known 
anti-inflammatory cytokines, cytokine inhibitors and inflammatory 
markers downstream in the acute-phase response, such as IL-1ra, 
IL-10 and sTNF-R [97,99]. Taken together, exercise provokes an 
increase primarily in IL-6, followed by an increase in IL-1ra and 
IL-10 (see Fig. (2)). Concentrations of the chemokines, IL-8, 
macrophage inflammatory protein  (MIP-1), and MIP-1 are 
elevated after strenuous exercise [149]. In most exercise studies, 
tumor necrosis factor (TNF-) does not change. When young, 
healthy men perform 180 min of a knee extensor exercise, TNF- 
mRNA increases only slightly (approximately fourfold, P=0.08) 
during the first 30 min of exercise, and after this time, it does not 
increase any further, whereas IL-6 increases ~ 100-fold in the same 
model [151,152]. Consistent with this, there is no measurable in-
crease in systemic levels, and there is not detectable TNF- net 
release from the working legs; only highly strenuous, prolonged 
exercise such as marathon running results in a small increase in the 
plasma concentration of TNF- [151,152]. 
 So, usually, the cytokine response to exercise and sepsis differs 
with regard to TNF-. Thus, physical exercise is associated with a 
systemic cytokine response comparable with the levels observed 
during severe infections or sepsis, except the important difference 
that increases in TNF- and IL-1 are really minute if present at all 
when concentric exercise without muscle damage is performed. 
 Following exercise, not necessarily the basal plasma IL-6 con-
centration might rapidly increase to the maximum levels reported 
(up to 100-fold respect to basal levels), infact less dramatic in-
creases are more frequent [12,153], instead major increase (up to 
8.000-fold) are exceptional and subsequent to extreme physical 
exercises [154]. The peak IL-6 level is reached at the end of the 
exercise or shortly thereafter [155], followed by a rapid decrease 
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towards pre-exercise levels. Young healthy individuals performed 3 
h of dynamic two-legged knee-extensor exercise at 50% of their 
individual maximal power output. This exercise induced an only 
moderate increase in heart rate (113 to 122 beats/min) but induced a 
16-fold increase in IL-6 mRNA, a 20-fold increase in plasma-IL-6, 
and a marked IL-6 release from working muscle [155]. When the 
same model was applied in elderly healthy untrained subjects, even 
higher amounts of IL-6 were released from working muscle during 
exercise at the same relative intensity [12]. Overall, the combina-
tion of mode, intensity, and duration of the exercise determines the 
magnitude of the exercise-induced increase of plasma IL-6 [12].  
 The discovery that IL-6 is released from contracting skeletal 
muscle has generated much interest among the scientific commu-
nity because this finding is somewhat paradoxical. On one hand, 
IL-6 is markedly produced and released in the postexercise period 
when insulin action is enhanced, but on the other hand, IL-6 has 
been associated with obesity and reduced insulin action. 
 An initial study suggested that increased systemic levels of 
inflammatory parameters were related to muscle damage, as in-
creased IL-6 levels were first detected in eccentric exercise models 
in which a positive correlation was also demonstrated to consider-
able creatine kinase (CK) increases [156]. However, later studies 
have not confirmed an association between peak IL-6 and peak CK 
levels. Moreover, it has become evident that eccentric exercise is 
not associated with a larger increase in plasma IL-6 than exercise 
involving concentric “nondamaging” muscle contractions, clearly 
demonstrating that muscle damage is not required to increase 
plasma IL-6 during exercise. Rather, eccentric exercise may result 
in a delayed peak and a slower decrease of plasma IL-6 during re-
covery [157-159]. 
 The IL-6 response is sensitive to the exercise intensity [160], 
which again indirectly represents the muscle mass involved in the 
contractile activity. Since contracting skeletal muscle per se is an 
important source of IL-6 found in the plasma [143,155], it is not 
surprising that exercise involving a limited muscle mass, e.g., the 
muscles of the upper extremities, may be insufficient to increase 
plasma IL-6 above pre-exercise level [161-163]. In contrast, run-
ning, which involves several large muscle groups, is the mode of 
exercise where the most dramatic plasma IL-6 increases have been 
observed. Fischer [153] has shown that exercise duration is the 
single most important factor determining the post-exercise plasma 
IL-6 amplitude. In fact, more than 50% of the variation in plasma 
IL-6 following exercise can be explained by exercise duration 
[153]. 
 Since exercise at high intensity is often associated with shorter 
duration of the exercise, and vice versa, the relationship between 
the plasma IL-6 increase and the duration may be even more pro-
nounced if adjusted for the exercise intensity. Accordingly, 6 min 
of maximal rowing ergometer exercise may increase plasma IL-6 2-
fold [164], but more than 10-fold increases of plasma IL-6 have not 
been observed in response to exercise lasting less than 1 h. 
 The fact that IL-6 is synthesized and released from contracting 
muscles alone and not from resting muscles exposed to the same 
hormonal changes [143,165]. In young men who perform a one-leg 
knee extensor exercise, IL-6 production in working muscles can 
account for the increase in plasma IL-6 during exercise when arte-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Overview of main known mechanisms through regular physical activity influences chronic systemic inflammation of atherosclerotic patient : 
Schematic representation of the main events of inflammation process in atherosclerosis and of the influence of myokines produced during muscle contraction. 
Broken arrows indicates inhibitory or regulatory effect of physical activity-induced anti-inflammatory mediators. See text for more details about the different 
mechanisms. 
ICAM-1, intercellular cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; IL, interleukin; 
IL-1ra: Interleukin-1 receptor antagonist; TNF-: tumor necrosis factor-alpha; VSMC: Vascular Smooth Muscular Cell; CRP: C-Reactive Protein; sTNF-Rs: 
soluble TNF; receptors; CD40L: CD40 ligand; LDL: Low Density Lipoprotein; ox- LDL: oxidized LDL 
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rial-femoral venous differences are measured over the exercising 
and the resting leg and adjusted for the blood flow [143]. This dem-
onstrates that circulating systemic factors cannot explain why con-
tracting muscles synthesize and release IL-6. It is more likely that 
local factors are involved, although systemic factors may modulate 
the IL-6 release from contracting muscle. Immunohistochemical 
studies of skeletal muscle have demonstrated that type 1 and type 2 
muscle fibers show marked and homogenous staining of IL-6 pro-
tein following exercise with a different, predominant accumulation, 
depending on the mode, intensity, and duration of the performance 
[165]. 
 After there was ascertained that contracting muscle is able to 
produce cytokines, a great part of the efforts of the studies in this 
matter were concentrated in the attempt to determine what was the 
source of the IL-6 production into the muscle. Being certain that 
monocytes are the main source of Il-6 during common immune 
response during sepsis or local infections, the first hypothesis tested 
was that immune cells were responsible of IL-6 increase during 
exercise [166], but early different groups demonstrated that IL-6 
mRNA in monocytes did not increase as a result of exercise 
[167,168]. These and other subsequent works clearly demonstrated 
that monocytes are not the source of the exercise-induced increase 
in plasma IL-6. Starkie et al. [169] demonstrated that the number, 
percentage, and mean fluorescence intensity of monocytes staining 
positive for IL-6 either do not change during cycling exercise [169] 
or do in fact decrease during prolonged running [170]. Excluded 
monocytes, seems today to be very clear that the contracting skele-
tal muscle per se is the main source of the IL-6 in the circulation in 
response to exercise. In resting human skeletal muscle, the IL-6 
mRNA content is very low, while small amounts of IL-6 protein 
predominantly in type I fibers may be detected using sensitive im-
munohistochemical methods [171]. In response to exercise, an in-
crease of the IL-6 mRNA content in the contracting skeletal muscle 
is detectable after 30 min of exercise, and up to 100-fold increases 
of the IL-6 mRNA content may be present at the end of the exercise 
bout [172,173]. Nevertheless this, although the earlier studies dem-
onstrated that IL-6 mRNA is increased in skeletal muscle biopsy 
samples, they did not prove that skeletal muscle is the source of the 
increase in the contraction-induced increase in IL-6. Today, it is not 
yet fully clear which cell type within the muscle is responsible for 
the production. 
 Whereas myoblasts had been shown to be capable of producing 
IL-6 [174,175], endothelial cells [176], fibroblasts [175], and 
smooth muscle cells [177] had been shown to produce IL-6 under 
certain circumstances. Langberg et al. [178] demonstrated that IL-6 
is produced by the peritendinous tissue of active muscle during 
exercise. In an attempt to determine which cells produce the IL-6, 
Keller et al. [179] isolated nuclei from muscle biopsies obtained 
before, during, and after exercise. In this work the authors demon-
strated that the nuclear transcription rate for IL-6 increases rapidly 
and markedly after the onset of exercise [179]. This suggested that 
a factor associated with contraction increases IL-6 transcriptional 
rate, probably in the nuclei from myocytes, given the observation 
that IL-6 protein is expressed within muscle fibers [180]. Further 
evidence that contracting muscle fibers themselves are a source of 
IL-6 mRNA and protein has been achieved by analysis of biopsies 
from the human vastus lateralis using in situ hybridization and im-
munohistochemistry [181,182]. In addition, assessment of the inter-
stitial IL-6 concentration using microdialysis indicates that the con-
centration of IL-6 within the contracting skeletal muscle may be 5- 
to 100-fold higher than the levels found in the circulation [183, 
184]. Accordingly, IL-6 appears to accumulate within the contract-
ing muscle fibers as well as in the interstitium during exercise. 
However, it has been the simultaneous measurement of arte-
riovenous IL-6 concentrations and blood flow across the leg that 
has demonstrated that large amounts of IL-6 are released from the 
exercising leg [143].  
 As mentioned above, very high concentrations of IL-6 have 
been detected along the Achilles’ tendon using microdialysis in 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic view of exercise-induced increases in circulating cytokines. ( [12], modified). 
The level of circulating IL-6 increases rapidly in an exponential fashion (up to 100-fold) in response to acute exercise and declines in the postexercise period. 
IL-6 levels elevation is followed by an increase of other anti-inflammatory cytokines, cytokine inhibitors and inflammatory markers downstream in the acute-
phase response, such as IL-1ra, sTNF-R, IL-10, IL-8 and IL-15 (the last two not showed in the graphic). Usually, TNF- levels do not increase in response to 
exercise. 
IL: Interleukin; sTNF-R: soluble Tumor Necrosis Factor – Receptor; TNF-: Tumor Necrosis Factor- . 
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response to prolonged running [183], but since the muscle mass 
involved in exercise is much higher than the mass comprised by 
tendons, the mutual contribution of peritendinous versus muscle-
derived IL-6 to the systemic IL-6 is unclear. In addition, a small net 
release of IL-6 from the internal jugular vein has been reported, 
suggesting that the central nervous system may contribute to the IL-
6 found in the circulation [185]. The findings are contrasted by the 
consistent findings that peripheral blood mononuclear cells do not 
contribute to the IL-6 found in the circulation of healthy subjects, 
neither at rest nor in response to exercise [169,187-188]. The adi-
pose tissue may contribute markedly to IL-6 in the circulation at 
rest [10,189]. However, although IL-6 mRNA levels increase in 
adipose tissue during exercise [190], measurement of arteriovenous 
plasma IL-6 differences across the abdominal subcutaneous adipose 
tissue bed shows that this compartment does not contribute to the 
exercise-induced IL-6 in the circulation until the recovery phase 
[191]. Since almost any cell type may synthesize IL-6 upon ade-
quate stimulation [192], further studies may discover other sites 
contributing to the IL-6 in the circulation in response to exercise. 
Is the Muscle IL-6 Release a Metabolic-related Event? 
 A very interesting aspect of the relationship between human 
skeletal muscle contraction and Il-6 release concerns the repeatedly 
confirmed data that about the observed autonomy of IL-6 produc-
tion from TNF-. It seems that this phenomenon rather than an 
inflammation-related event could be metabolic-related [193,194].  
 During exercise, skeletal muscles need to increase the uptake of 
glucose and FFA to generate adenosine 5-triphosphate (ATP) and to 
quickly refill glycogen pools. Several metabolic genes are transcrip-
tionally activated in the recovery phase from exercise, presumably 
with the purpose to rebuild energy stores [194]. If IL-6 is an energy 
sensor in the muscle, and IL-6 is released when the local glycogen 
content is low, it is possible that the large amounts of muscle-
derived IL-6 in the circulation act as a hormone with the purpose to 
mobilize extracellular substrates and/or to augment substrate deliv-
ery during exercise [145]. So, this interesting link between IL-6 
production and muscle metabolism seems to have a strong relation 
to glycogen muscular content. both intramuscular IL-6 mRNA ex-
pression [145] and protein release [146] are exacerbated when in-
tramuscular glycogen is compromised, suggesting that IL-6 is 
somehow related to glycogen content. 
 IL-6 induces lipolysis and increased fat oxidation without caus-
ing triacylglycerolemia when it is administrated in doses mimicking 
systemic levels during exercise [195] as well as higher doses [196]. 
Consistent with this, IL-6 induces lipolysis in 3T3-LI adipocytes 
and increases fat oxidation in myotubes and in isolated rat soleus 
muscle [197]. In addition, it has been suggested that IL-6 influences 
glucose homeostasis during exercise [198-200]. In the latter study, 
young men performed a bicycle exercise at three separate occa-
sions, at a relative high intensity or at a low intensity, with or with-
out an infusion of recombinant (r)IL-6, which matched the circulat-
ing concentration of IL-6 in the high-intensity trial. It was demon-
strated by the use of stable isotopes that the endogenous glucose 
production, whole-body glucose disposal, and the metabolic clear-
ance rate of glucose were higher during the rIL-6 infusion + low 
intensity exercise than low-intensity exercise alone, despite identi-
cal exercise intensities and the same levels of insulin, glucagon, 
epinephrine, norepinephrine, cortisol, and growth hormone [165]. 
This finding implicates an entirely novel understanding of the role 
for IL-6 in glucose production and clearance. 
 Adding to what we knew about this topic, recently a number of 
studies have clearly demonstrated that glucose ingestion during 
exercise attenuates the exercise-induced increase in plasma-IL-6 
[195,197-200]. This effect has been demonstrated for different 
types of training, for example running or cycling [199,200]. How-
ever, whereas supplementation with carbohydrates during exercise 
inhibits the exercise-induced increase of IL-6 in plasma, IL-6 
mRNA expression within the contracting muscle is unaffected 
[201,202]. As carbohydrate availability is reduced, the sympatho-
adrenal response to exercise is exacerbated, and it has been sug-
gested that epinephrine may stimulate IL-6 gene transcription via -
adrenergic stimulation of protein kinase A. 
 Accordingly to this experimental observations, there is evidence 
in support of the hypothesis that during physical exercise, IL-6 has 
the capacity to act in a “hormone-like” manner to direct the metabo-
lism toward enhanced energy supply to working skeletal muscles, 
exerting especially strong effects on adipose tissue. 
 During acute exercise, in addiction to high circulating levels of 
IL-6 and subsequently IL-1ra, IL-10 and sTNF-R, also other 
myokines are secreted: IL-8 and IL-15. 
 IL-8 belongs to the CXC family of chemokines. The CXC no-
menclature relates to the presence of two conserved cysteine resi-
dues at the NH2 terminus separated by one amino acid. IL-8 is a 
known chemokine that attracts primarily neutrophils. In addition to 
its chemokine properties, IL-8 acts as an angiogenic factor. 
 IL-8, like IL-6, is influenced by physical activity. The systemic 
plasma concentration of IL-8 increases in response to exhaustive 
exercise such as running, which involves eccentric muscle contrac-
tions [203-205]. In contrast, concentric exercise such as bicycle 
ergometry [206] or rowing [207] of moderate intensity does not 
increase plasma IL-8 concentration. However, intense cycle er-
gometry has been reported to increase IL-8 plasma concentration to 
a small degree [208]. The possibility of contracting skeletal muscle 
expressing IL-8 has been evaluated by Nieman et al. [203]. These 
authors showed that a severalfold increase in IL-8 mRNA could be 
found in skeletal muscle biopsies from subjects having completed a 
3-h treadmill run concomitantly with increased plasma levels of IL-
8 [203]. Similarly, IL-8 mRNA increased in response to 1 h of cy-
cle ergometry exercise, but with no change in the plasma concentra-
tion of IL-8 [206]. IL-8 protein was recently demonstrated to be 
clearly expressed in human skeletal muscle as a response to concen-
tric exercise [209]. The finding of a marked increase of IL-8 mRNA 
in muscle biopsies during and following exercise, and IL-8 protein 
expression within skeletal muscle fibers in the recovery from exer-
cise, strongly indicates that exercise per se stimulates muscle cells 
to produce IL-8. This is in accordance with the finding that muscle 
cells in vitro have the capacity to express IL-8 both at the mRNA 
and protein levels [210]. 
 The physiological function of IL-8 within the muscle is still 
unknown. The main part of the systemic increase in IL-8 as seen 
during exercise with an eccentric component is most likely due to 
an inflammatory response. In accordance with this, several groups 
observed that there is not increase in the systemic IL-8 plasma con-
centration during or after concentric exercise [203,206,209]. How-
ever, when measuring the arteriovenous concentration difference 
across a concentrically exercising limb, we detected a small and 
transient net release of IL-8, which did not result in an increase in 
the systemic IL-8 plasma concentration [209]. The fact that a high 
local IL-8 expression takes place in contracting muscle with only a 
small and transient net release may indicate that muscle-derived IL-
8 acts locally and exerts its effect in an autocrine or paracrine fash-
ion. A plausible function of the muscle-derived IL-8 would be 
chemo-attraction of neutrophils and macrophages when, in fact, in 
concentric exercise there is little or no accumulation of neutrophils 
or macrophages in skeletal muscle.  
 A more likely function of muscle-derived IL-8 is to stimulate 
angiogenesis. IL-8 associates with the CXC receptor 1 and 2 
(CXCR1 and CXCR2). It induces its chemotactic effects via 
CXCR1, whereas CXCR2, which is expressed by human microvas-
cular endothelial cells, is the receptor responsible for IL-8-induced 
angiogenesis [211-213]. 
 IL-15 (14-15 kDa) is a four--helix cytokine with structural 
similarities to IL-2 [214,215]. Two isoforms of IL-15 with altered 
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glycosylation have been shown to exist: a long signaling peptide 
form (48 amino acids) that is secreted from the cell, and a short 
signaling peptide (21 amino acids) form that remains intracellular, 
localized to nonendoplasmic regions in both cytoplasmic and nu-
clear compartments. Cell membrane expression might be crucial in 
mediating an extracellular function rather than secretion and, in 
part, explains the difficulty in detecting soluble IL-15 in biological 
systems. IL-15 functions via a widely distributed heterotrimeric 
receptor (IL-15R), which consists of a -chain (shared with IL-2). 
 The regulatory role of muscle contraction with regard to IL-15 
is unclear. Nieman et al. (203) found that muscle IL-15 mRNA 
levels were unchanged immediately after a 3-h run, and Ostrowski 
et al. [216] found that plasma IL-15 (measured up to 6 h into recov-
ery) did not change in response to 2.5 h of treadmill running. Skele-
tal muscle IL-15 mRNA levels, measured immediately after a 2-h 
weight training bout, did not differ from baseline [199], whereas 
plasma IL-15 protein was increased immediately after acute resis-
tance exercise in one study [217]. 
 IL-15 has been identified as an anabolic factor, which is highly 
expressed in skeletal muscle [218]. Furthermore, IL-15 has been 
suggested to play a role in muscle-adipose tissue interaction [219]. 
In human skeletal myogenic cultures, IL-15 induces an increase in 
accumulation of the protein myosin heavy chain (MHC) in differen-
tiated muscle cells, suggesting IL-15 as an anabolic factor in muscle 
growth [220], and IL-15 stimulates myogenic differentiation inde-
pendently of insulin-like growth factors (IGFs) [221]. Moreover, in 
opposition to the growth factor IGF-I, IL-15 has effects on fully 
differentiated myoblasts [222]. The potential therapeutic effect of 
IL-15 was demonstrated in an in vivo model, which demonstrated 
that IL-15 was able to antagonize the enhanced muscle protein 
breakdown in a cancer cachexia model. Interestingly, while IL-15 
has been reliably demonstrated to have anabolic effects on skeletal 
muscle in vitro and in vivo, IL-15 seems to play a role in reducing 
adipose tissue mass. When IL-15 was administered to adult rats for 
7 days, it resulted in a 33% decrease in white adipose tissue mass 
[223]. These findings provide support for the hypothesis that IL-15 
functions in a muscle-to-fat endocrine axis that modulates fat: lean 
body composition and insulin sensitivity. 
 The list of the substances providing relevant metabolic effects 
produced by skeletal muscle fibres during contraction is rapidly 
increasing. It has recently been reported that adiponectin mRNA 
and protein are also expressed in skeletal muscle in response to in 
vivo lipopolysaccharide (LPS) administration in mice and following 
in vitro incubation with TNF- and IFN- in combination, but not 
IL-6 or IL-1 in human myotubes [224]. 
 Adiponectin is an adipocytokine product of adipose tissue, 
which exerts insulin-sensitizing activity on the liver and skeletal 
muscle, antiatherogenic, and antiinflammatory effects, and inhibits 
TNF- production and endothelial activation induced by TNF- 
[224]. An important autocrine/paracrine factor in adipose tissue, it 
modulates the differentiation of preadipocytes and favors the for-
mation of mature adipocytes. 
 It is well assumed that adiponectin concentrations are lower in 
obese than lean individuals. This is one of the main metabolic 
changes linking adipokines with the systemic pro-inflammatory 
asset observed in the patients affected by the metabolic syndrome, 
infact this adipokine functions as an endocrine factor, influencing 
whole-body metabolism via effects on target organs: adiponectin 
exerts multiple biologic effects pivotal to cardiovascular biology, 
including increasing insulin sensitivity, reducing visceral adipose 
mass, reducing plasma triglycerides, and increasing high-density 
lipoprotein (HDL) cholesterol [224]. Adiponectin, furthermore, 
alters the concentrations and activity of enzymes responsible for the 
catabolism of triglyceride-rich lipoproteins and HDL, such as lipo-
protein lipase and hepatic lipase. All this alterations of the meta-
bolic and lipid profile might affect atherosclerosis by modifying the 
balance of atherogenic and antiatherogenic lipoproteins in plasma. 
Adiponectin also directly affects the function of endothelial cells, 
reducing VCAM-1 expression, and macrophages, decreasing the 
expression of scavenger receptors through the modulation of the 
production of TNF-.  
Acute Exercise is a Pro-oxidant Stimulus  
 Given that acute exercise is associated to a circulating release of 
myokines with a change in systemic immunologic state that is able 
to interfere with low-grade chronic inflammation of several patho-
logic conditions, it is also well demonstrated that acute exercise 
promotes oxidative stress. This finding, mediated by whole-body 
considerable increase of VO2 (oxygen consumption) during exer-
cise could also seems paradoxical, such as the circulating release 
during exercise of pro-inflammatory cytokines such as IL-6. 
 The finding that exercise promotes oxidative stress in humans 
was first reported over 30 years ago, in 1978 [225]. This work re-
vealed that 60 min of endurance exercise at 60% of VO2 max re-
sults in increased levels of expired pentane (biomarker of lipid per-
oxidation) and that supplementation with the antioxidant vitamin E 
reduced both resting and exercise-induced pentane production. The 
authors concluded that exercise promotes increased oxidant produc-
tion but the source of this increased oxidant production was uniden-
tified. Since this early observation, many studies using both animal 
and human subjects have demonstrated that a variety of exercise 
intensities and exercise modes (e.g., cycling, running, and resis-
tance exercise) result in increased biomarkers of oxidative damage 
in both blood and skeletal muscle [226-230]. Only few studies have 
tried to find out the primary sources of reactive oxygen species 
(ROS) production during exercise, although we know that several 
tissue can produce ROS during exercise [231]. The lack of in vivo 
studies on this topic is due to the difficulty of investigating the mul-
tifaceted nature of exercise, which involves several organ systems 
that are connected through the increased energy requirement of 
contracting skeletal muscles [231]. Since the discovery that con-
tracting skeletal muscles produce ROS [225], many investigators 
have assumed that skeletal muscle provides the major source of free 
radical and ROS generation during exercise [231]. Nonetheless, 
other tissues such as the heart, lungs, or blood may also contribute 
to the total body generation of ROS during exercise [231,232].  
 Studies about local consequences of ROS production in skeletal 
muscle showed how ROS influence the skeletal muscle force pro-
duction in both unfatigued and fatigued muscle.  
 The low levels of ROS present in skeletal muscle during basal 
conditions are a requirement for normal force production [233,234]. 
Indeed, depletion of ROS from unfatigued skeletal muscle results in 
decreased muscle force production [235-237]. In contrast, a small 
increase in ROS production in skeletal muscle fibers promotes an 
increase in force production [235] (see Fig. (3)). The positive im-
pact of ROS on muscle force production is reversed at high ROS 
concentrations as force production decreases in a dose-dependent 
manner [235]. So, local skeletal muscular cellular redox distur-
bances can significantly reduce skeletal muscle force production. 
This consistent observation suggests that contraction-induced ROS 
production can contribute to muscular fatigue during prolonged and 
intense exercise. Obviously, systemic spillover of redox muscular 
abnormalities cause a response due to anti-oxidant activity of spe-
cific enzymes, clearly seen during chronic adaptations to training. 
 Into the cell the increased oxygen flux through the mitochon-
drial electron transport chain is believed to be the main source of 
free radical generation during exercise, but many metabolic path-
ways differently in various tissues contribute to the generation of 
free radicals by reactions during exercise through the induction of 
enzymes such as xanthine oxidase, NADPH oxidase and myeloper-
oxidase [238]. The induction of these pro-oxidant enzymes by 
skeletal muscle and other tissues leads to an increase in plasma  
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Fig. (3). Hypothetical model linking skeletal muscle redox state and force 
production proposed by Reid et al. in 1993 ([235], modified). 
Low levels of reactive oxygen species (ROS) from unfatigued skeletal mus-
cle results in decreased muscle force production. In contrast, a small in-
crease in ROS production in skeletal muscle fibers promotes an increase in 
force production. The positive impact of ROS on muscle force production is 
reversed at high ROS concentrations as force production decreases in a 
dose-dependent manner. See text for more details.  
 
markers of oxidative stress, such as F2-isoprostanes and myeloper-
oxidase. Circulating levels of these markers are independently asso-
ciated with CVD risk [239,240], but it is unclear if oxidative stress 
in the circulation directly promotes the oxidation of LDL in the 
vascular wall and so could promote or exacerbate the atheroscle-
rotic damage. Further elements about this concept are provided by 
Wetzstein et al. [241], who have shown that acute exercise in-
creases the susceptibility of LDL to undergo in vitro oxidation, 
implying that this may also happen in the circulation. However, ox-
LDL in the plasma is cleared rapidly by the liver [242], so probably 
the circulating oxidation of LDL particles does not necessarily 
promote inflammation like LDL that is oxidized and retained in the 
artery wall. There is even evidence that plasma oxidative stress may 
be atheroprotective. Meilhac et al. [243] have shown that acute 
exercise in mice increases antibodies to oxidatively modified lipo-
proteins in the plasma, but this was associated with the induction of 
the antioxidant enzyme catalase in the vascular wall after just 1 
week of exercise. This indicates that an exercise- induced plasma 
oxidative stress may stimulate an arterial antioxidant response, 
which should inhibit LDL oxidation, inflammation and ultimately 
atherosclerosis [243]. Additional studies are needed to confirm this 
hypothesis. 
 In contrast to acute exercise, chronic exercise appears clearly to 
enhance antioxidant defences in skeletal muscle, the circulation and 
the vasculature by a variety of mechanisms. In skeletal muscle, 
exercise training increases the activity of the antioxidant enzymes 
glutathione peroxidise and SOD (superoxide dismutase) [238]. 
These adaptations may dampen the metabolic perturbations in 
skeletal muscle induced by bouts of acute exercise. Chronic exer-
cise also reduces markers of oxidative stress in the plasma, includ-
ing F2-isoprostanes [244] and myeloperoxidase [245]. In the vascu-
lature, exercise training induced increases in eNOS activity have 
many direct and indirect effects on oxidative stress and inflamma-
tion. Lastly, endothelium-derived NO may reduce inflammation in 
the artery wall by inhibiting activation of NF-B (nuclear factor 
B). NF-B is a transcription factor that is involved in the regula-
tion of many of the pro-inflammatory genes linked to atherosclero-
sis, and probably mediates many of the anti-atherogenic effects 
ascribed to NO, including inhibiting leucocyte binding and chemo-
taxis, the aggregation of platelets and the proliferation of SMCs 
[reviewed in 61]. As a result, the exercise-induced induction of 
eNOS may be responsible for a significant part of the anti-
inflammatory effects of exercise training in the vascular wall. 
PART III - EFFECT OF CHRONIC EXERCISE TRAINING 
ON INFLAMMATORY MARKERS OF ATHEROSCLERO-
SIS 
 In the latest reviews regarding the pathophysiology of athero-
sclerosis, matters such as vascular wall inflammation, chronic sys-
temic low-grade inflammation and endothelial dysfunction seems to 
play very important roles. These three conditions are strictly linked 
one another. It is well known that the atherosclerotic plaque begins 
with a focal endothelial cell dysfunction [246,247]. This includes 
the overexpression of cellular adhesion molecules, which promote 
the recruitment of blood mononuclear cells, and the enhancement of 
the endothelial layer permeability, in turn facilitating the diffusion 
of low-density lipoproteins (LDL) to the intima [246,247]. Circulat-
ing leucocytes do not adhere to the healthy endothelium; but during 
lesion formation the endothelium expresses cell adhesion molecules 
(CAMs), including vascular cell adhesion molecule-1 (VCAM-1) 
and intercellular adhesion molecule-1 (ICAM-1), to which circulat-
ing leucocytes selectively attach [247, 248]. In the same way, 
chemoattractant stimuli originated in the vascular wall promote 
migration of leukocytes into the intima, where the macrophage 
colony-stimulating factor stimulates the differentiation of mono-
cytes into macrophages [1,248]. The macrophages express scaven-
ger receptors that allow them to engulf and modify oxidized lipo-
proteins and become foam cells [247,248] 
 This is the vascular event that promote the secretion of several 
number of inflammatory mediators, such as the cytokines, of which 
has been discussed previously in this paper. Progressive amplifica-
tion of vascular inflammation can contribute to additional leukocyte 
accumulation, smooth muscle cell proliferation, and extracellular 
matrix remodelling [247,248]. This local inflammatory response 
sustained by primary pro-inflammatory cytokines (IL-1 and TNF-) 
further stimulates the production of IL-6 in several cell types, in-
cluding smooth muscle cells and endothelial cells, which magnify 
the inflammatory response beyond the original focal area of endo-
thelial dysfunction. Therefore, the increased circulating levels of 
IL-6 will further induce the hepatic synthesis of acute-phase pro-
teins, including fibrinogen, CRP and serum amyloid A.  
 In this background, IL-6 acts as an amplifier of the acute-phase 
response, which is accountable for the augment of the expres-
sion/production of adhesion molecules, other cytokines, endothelin-
1, endothelial plasminogen activator inhibitor-1, tissue factor in 
monocytes, LDL uptake by macrophages, and for the diminution of 
nitric oxide (˙NO) bioavailability [249,250]. Simultaneously, the 
inflammatory response inhibits the production of collagen and 
stimulates macrophage expression of the potent procoagulant tissue 
factor, contributing to the prothrombotic blood environment nearby 
the areas of endothelial dysfunction [247,248]. Macrophage activity 
within the vascular wall may also contribute to plaque vulnerability 
and enhanced risk of plaque rupture, by elaborating matrix metallo-
proteinases which degrade the protective collagen structure of the 
plaque's fibrous cap, and consequently lead to the formation of 
thrombi that could lead to acute coronary events [247,248]. 
 So, endothelial cell integrity is essential for preserving vascular 
homeostasis, allowing the continuous adjustment of vascular tone, 
the physiological regulation of leukocyte traffic, and the mainte-
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nance of blood fluidity [251]. In several pathological conditions, 
such as in atherosclerosis, the endothelial function is chronically 
disturbed in local areas. Endothelial dysfunction is characterized by 
an alteration in the basal endothelial phenotype (vasorelaxant, anti-
coagulant, antiplatelet and profibrinolytic), to one that is vasocon-
strictive, procoagulant, platelet-activating, and antifibrinolytic 
[252,253]. The dysfunctional endothelial cells release lower levels 
of ˙NO, prostacyclin, thrombomodulin and tissue plasminogen acti-
vator and meanwhile increase levels of endothelin-1, angiotensin II, 
plasminogen activator inhibitor (PAI)-1 and von Willebrand factor 
[254]. Tissue factor, which is not present on the functional endothe-
lial cell surface, becomes expressed as a result of thrombin produc-
tion. Thrombin is activated through the binding of activated factor 
V to activated factor X on the surface of the endothelial cell [252]. 
The utility of these molecules could be to serve as novel biomarkers 
of “endothelial health”, whereby the effect of various therapeutic 
strategies could be monitored. Additionally, such strategies could 
be employed to explore the various mechanisms of exercise training 
upon the vascular endothelium in states of health and disease. 
 According to the current knowledge, regular exercise is a non-
pharmacological therapeutic modality that enhances endothelial 
function in subjects with cardiovascular risk factors, including hy-
percholesterolemia [255], hypertension [29,256], metabolic syn-
drome [257], and type 2 diabetes mellitus [24,258], and in patients 
with established CAD [259,260] and heart failure [27,28,261]. In a 
prospective clinical study with CAD patients, 4 weeks of intensive 
exercise training decreased the coronary artery vasoconstriction, in 
response to acetylcholine, by 54% [259]. Additionally, the follow-
up of those patients indicated that the continuation of regular exer-
cise, in a home-based program, could sustain, at least partially, the 
previously achieved effects on coronary endothelial function [261]. 
 The augment of ˙NO bioavailability induced by exercise could 
be the result of the increased activity/expression of eNOS, and/or 
the diminished degradation of ˙NO in result to the reduced interac-
tion with ROS Fig. (2). Studies using animal experiments [262,263] 
and cultured endothelial cells [264,265] suggested that shear stress 
increases eNOS expression/activity, probably due to the stabiliza-
tion of eNOS mRNA [264] or the presence of transcription factors 
in the promoter region of eNOS gene enhancing the synthesis of 
mRNA [266]. Hambrecht et al., in 2003 [267], performed the first 
study demonstrating the positive effects of exercise training on 
vascular function and eNOS expression in the human vascular sys-
tem. The authors found a 2-fold increase in eNOS mRNA expres-
sion and a 3.2 increase in the phosphorylation of eNOS on serine 
1177 residue after 4 weeks of regular exercise training in CAD 
patients. This led to a rise in the enzymatic activity of eNOS and 
consequently to an enhanced ˙NO production. Furthermore, regular 
exercise tends to increase the antioxidant defenses and by this way 
reduce the ˙NO degradation [268]. This hypothesis was verified in 
heart failure patients in whom exercise improved ˙NO-dependent 
vasodilatation without changes in eNOS expression. This was ex-
plained through the increase of antioxidant defences, such as the 
enhanced activity of Superoxide 
 Dismutase and Glutathione Peroxidase [269]. Moreover, in 
vitro studies showed that the application of laminar shear stress to 
cultured endothelial cells activates eNOS as well as the cytosolic 
copper/zinc containing Superoxide Dismutase pathway [270,271, 
272,273]. This increase in the antioxidant defences, observed both 
in myocardium and endothelial cells [271,272,273,274], seems to 
result from repetitive exposure to increased laminar shear stress 
during acute bouts of exercise training. The increase of antioxidant 
defences could also contribute to attenuating the formation of foam 
cells and vascular inflammation through the reduction of a crucial 
step in the atherogenesis: the LDL oxidation [275,276]. Indeed, the 
lipid oxidation, as the result of LDL exposure to the oxidative waste 
of intima layer, seems to be paramount to the foam cells formation, 
as native LDL is rapidly taken up by macrophages [247].  
 In summary, regular exercise promotes the acute increase of 
blood flow and shear stress and, in turn, improves the ˙NO 
bioavailability, hence increasing the endothelium-dependent vaso-
dilatation. This improvement could represent one of the most im-
portant mechanisms explaining the reduction of myocardial ische-
mia through regular exercise [259,267]. However, it should be 
noted that exercise intensity seems to be a crucial variable in this 
response. It is well established that moderate-intensity aerobic exer-
cise augments endothelium-dependent vasodilatation in subjects 
with impaired endothelial function [277,278]. Nevertheless, recent 
studies in metabolic syndrome subjects [279] and heart failure pa-
tients [280] have shown that high intensity aerobic interval exercise 
was better than moderate-intensity aerobic exercise to increase en-
dothelial function and ˙NO availability. Wisløff et al. [280] sug-
gested that the superior effect of aerobic interval training could be 
elicited by higher shear stress during the acute bouts of exercise, 
which triggers larger responses at the cellular and molecular level. 
Effects of Regular Physical Exercise on CRP and other In-
flammatory Markers of Atherosclerosis 
 An increasing number of studies have examined the anti-
inflammatory potential of chronic exercise through the assessment 
of circulating levels of several systemic markers of inflammation, 
first of all CRP (see Table 1). Nevertheless the discrepancies 
among the studies and the different behaviour of various classes of 
inflammatory markers in response to training, taken together the 
data from the main studies regarding this matter seem to indicate 
that exercise training might reduce the circulating levels of markers 
of inflammation.  
 The activation of the endothelial cell by cytokines, oxidized 
LDL, and ROS induce the endothelial expression of CAMs, such as 
ICAM-1, VCAM-1, E-selectin, and P-selectin, that are crucial to 
the recruitment of inflammatory cells to the vessel wall [281,282]. 
These molecules can be measured in circulation as soluble adhesion 
molecules since they are released in soluble form into the blood-
stream from the proteolytic cleavage of membrane bound mole-
cules. 
 Therefore, these molecules are considered to be important 
markers of endothelial cell activation and inflammation [282]. Ex-
ercise training seems to have a positive impact in the circulating 
CAMs. In subjects at risk of coronary events, two weeks of exercise 
training reduced circulating levels of soluble ICAM-1 [283]. Like-
wise, in heart failure patients, exercise training decreased the circu-
lating levels of soluble ICAM-1, VCAM-1 [284], and P-selectin 
[285]. Also in animal experiments, exercise training performed 5 
times per week for 6 to 8 weeks induced a significant decrease in 
the expression of P-selectin and VCAM-1 [286,287]. This positive 
impact of exercise on circulating CAMs could be related to changes 
in the transcriptional regulation of CAMs induced by shear stress 
[288]. Besides this direct influence in CAMs expression, exercise 
training might also have indirect favourable effects throughout the 
reduction of agonists of CAM synthesis, namely inflammatory cy-
tokines [289], ROS [270,271], and, thus, the oxidation of LDL 
[275,276]. By reducing the soluble adhesion molecules, which may 
represent the interaction between activated monocytes/macrophages 
and endothelial cells, exercise training might be considered an ef-
fective non-pharmacological intervention to reduce endothelial 
adhesiveness. 
 Several prospective studies [289-294] examining the influence 
of exercise training alone or incorporated in more composite ap-
proaches associated to cardiac rehabilitation programs or other 
lifestyle interventions on markers of inflammation, have suggested 
an anti-inflammatory effect of chronic exercise (see Table 1). How-
ever, the majority of those studies are nonrandomized, uncontrolled, 
and observational.  
 Milani et al. [295,296] conducted the first studies assessing the 
effects of cardiac rehabilitation and exercise training on the plasma  
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Table 1. Selected Studies that Examined the Effects of Exercise Training on Inflammatory Markers of Atherosclerosis 
Study  [reference]  Duration  Intervention  Inflammatory 
Parameter(s)  
Main Findings  
Smith et al. 1999 [294] 6 months  Exercise (different 
types)  
CRP  35% decrease in serum levels of CRP (P=0.12).  
Mattusch F et al 2000 
[318]  
9 months  Endurance training  CRP  Healthy subjects preparing for a marathon. CRP decreased 
from 1.19 mg/L before to 0.82 mg/L after training (p < 0.05).  
Milani et al. 2003 [296]  12 weeks  Cardiac rehabilita-
tion  
CRP  Significant reduction in CRP after the 3-month intervention in 
CAD patients with and without metabolic syndrome (P < 
0.001)  
Milani et al. 2004 [295]  12 weeks  Cardiac rehabilita-
tion  
hsCRP  CAD patients. Median levels of hsCRP in tretated group: -
41% (p = 0.002)  
Rauramaa et al 2004 [322]  6 years  Low to moderate 
Aerobic exercise  
hsCRP  Nonsignificantly change of hsCRP in the exercise group vs 
the control group (P > 0.2)  
Caulin-Glaser et al. 2005 
[297] 
12 weeks  Cardiac rehabilita-
tion  
CRP  CHD patients. CRP decreased from 5.7 to 2.7 mg/L (P:0.003). 
Decrease became unsignificant based on age or the presence 
of metabolic syndrome.  
Goldhammer et al. 2005 
[289]  
12 weeks  Cardiac rehabilita-
tion  
L-1, IL-6, IL-
10, INF-, 
CRP)  
CAD patients. Reduction in CRP, IL-1, IL-6, INF- levels, 
and increase in IL-10.  
Niessner et al. 2006 [293] 12 weeks  Aerobic exercise  IL-8, MCP-1, 
MMP-9, IL-6, 
hsCRP  
High risk CAD patients.  Significant decrease of IL-8  (p: 
0.002), MCP-1 (p:0.03) and MMP-9  (p: 0.05) levels. Il-6 and 
hsCRP did not change in response to training.  
Huffman et al. 2006 [303] 6 months  Exercise (different 
types)  
hsCRP  Sedentrary obese and dyslipidemic. Despite significant im-
provements in fitness, visceral adiposity, and insulin sensitiv-
ity, hsCRP did not change in response to exercise training (P 
> .20).  
Kohut ML et al [316] 10 months  Aerobic exerecise 
vs flexibil-
ity/strength exer-
cise  
CRP, IL-6, 
TNF-, IL-18  
Aerobic training reduced CRP, IL-6, and IL-18 compared to 
the strenght treatment whereas TNF- declined in both 
groups.  
Shin et al. 2006 [301] 14 weeks  Cardiac Rehabili-
tation*  
hsCRP, Il-6  Significant reduction of IL-6 and hsCRP (- 58.3 %, p: 0.01)  
Stewart  et al. 2007 [320] 12 weeks  aerobic and resis-
tance training  
CRP, IL-1, 
IL-6, TNF-  
Serum CRP decreased with training whereas Plasma IL-6 and 
IL-1beta did not change. TNF- was higher after the training 
period.  
Pluss et al. 2008 [298] 12 weeks  Cardiac Rehabili-
tation **  
CRP  AMI or CABG patients.  CRP decreased from 3.04 to 2.09 
mg/L in the intervention group (p< 0.01).  
Kim et al. 2008 [291] 14 weeks  Cardiac Rehabili-
tation  ***  
hsCRP, TNF-
, IL-6  
CAD patients. TNF- (by 20.4%; p = 0.006) IL-6 (by 49.0%; 
p < 0.0001), and hsCRP (by 59.4%; p < 0.0001), were mark-
edly decreased after CR  
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(Table 1) Contd.... 
 
Study  [reference]  Duration  Intervention  Inflammatory 
Parameter(s)  
Main Findings  
Walther et al. 2008 [290] 24 months  Exercise vs PCI  hsPCR, IL-6  CAD patients needing revascularization. In a subgroup of 
patients, hsCRP and IL-6 levels were significantly reduced by 
41 and 18%, respectively, whereas no relevant changes were 
observed in the PCI group.  
Sixt et al. 2008 [299] 4 weeks  Exercise vs rosigli-
tazone  
CRP, fibrino-
gen  
CAD and IGT patients.  CRP and fibrinogen levels did not 
change significantly (p > 0.05)  
Harvinder et al 2010 [326]  12 weeks  Cardiac Rehabiili-
tation  ^  
CRP, IL-6  CAD patients. Significant decreases occurred in CRP (from 
2.07 to 1.6 mg/L, p = 0.03) and IL-6 (from 2.52 to 1.23 pg/ml, 
p = 0.02)  
CRP = C-reactive protein; IL: Interleukin; PCI = percutaneous intervention; CR = cardiac rehabilitation; CAD= Coronary Artery Disease; CHD= Coronary Heart Disease; MCP-1 = 
Monocyte chemoattractant protein-1; MMP: Metalloproteinase; AMI= Acute Myocardial Infarction; CABG= coronary artery by-pass grafting; IGT= Impaired glucose tolerance;  
* Cardiac Rehabilitation Therapy in this RCT consisted of a supervised 6 weeks of exercise following hospital discharge and 8 weeks of home stay exercise. 
** “Expanded” Cardiac Rehabilitation in this RCT consisted of multifactorial interventions on metabolic and inflammatory markers, exercise performance and on established cardio-
vascular risk factors. 
*** Cardiac Rehabilitation in this RCT consisted of 6 weeks supervised exercise training and 8 weeks home-based, self-managed exercise. 
^ the “Multisite Cardiac Lifestyle Intervention Program” performed in this trial consisted of change in diet (10% calories from fat, plant based), engage in moderate exercise (3 
hours/week), and practice stress management (1 hour/day). 
 
levels of CRP. They found a significant reduction in CRP after the 
3-month intervention in CAD patients with and without metabolic 
syndrome [296], in weight gainers and losers [295], and in patients 
with or without statin therapy [295]. This data was later confirmed 
by Caulin-Glaser et al. [297], who reported a consistent reduction 
of CRP in patients who showed no improvement or an increase in 
triglycerides, body mass index, and weight. Others [289,290,298] 
also observed the statins and weight loss-independent effects of 
exercise on CRP and other markers of inflammation. Goldhammer 
et al. [289], determining the effect of aerobic exercise training on 
levels of pro- and anti-inflammatory cytokines, IL-1, IL-6, IL-10, 
INF-, and CRP in CAD patients participating in a cardiac rehabili-
tation program found a significant reduction of CRP levels after 12 
weeks of training. Cardiac training was associated with a 40.5% 
CRP reduction in enrolled patients compared to 19% reduction in 
non-diabetics (p < 0.01). Training resulted in a significant reduction 
of all pro-inflammatory cytokines, IL-1, 0.33 ± 0.23 to 0.51±0.12 
pg/ml, p=0.014, IL-6, 2.50±1.50 to 1.44±0.57 pg/ml, p=0.002, INF-
, 18.63±3.31 to 16.77±2.49 pg/ml, p<0.001, as well as a significant 
increase in the anti-inflammatory, cytokine IL-10, from 1.61±1.40 
to 2.29±2.01 pg/ml, p=0.008, obtaining an effective reduction of all 
the inflammatory markers [289]. 
 In another interesting study, Walther et al. [290] randomized 
101 patients with stable CAD but an indication for revascularization 
to either percutaneous intervention with stent or aerobic exercise 
training. In a subgroup of 66 patients, after 24 months of training, 
CRP levels were reduced by 41% and IL-6 levels by 18 % whereas 
no change was observed in the percutaneous intervention group. 
The effects of exercise were independent of statin therapy. There-
fore, this data suggests that cardiac rehabilitation and exercise train-
ing has an anti-inflammatory effect independent of statin therapy 
and weight loss.  
 As pointed out in the Table 1, the majority of evidence suggests 
that exercise training is related with ameliorations in biomarkers of 
systemic low-grade inflammation expressed by the circulating lev-
els of CRP. However, not all the studies are univocal to confirm 
this relationship, infact two recent studies [299,300] failed to con-
firm this effect. This discrepancy may be due to a number of fac-
tors, including differences in subject characteristics and number, the 
timing of the blood samples taken, and the type, and the intensity 
and duration of the exercise intervention. Indeed, the duration of the 
intervention seems to be crucial, since the majority of studies show-
ing improvements in the markers of inflammation included at least 
a 12-week exercise intervention. The two studies mentioned previ-
ously included 4 [299] and 7 [300] weeks of exercise training. It is 
interesting to note that levels of CRP showed a trend of decreasing 
following the 7-week intervention. They decreased by 17.4%, al-
though without reaching statistical significance, suggesting that 
probably a longer intervention is needed to induce significant im-
provement in the inflammatory status of atherosclerotic patients, 
similarly to what occurred in other studies cited in Table 1, in 
which duration of intervention seem able to induce the obtaining of 
significance in CRP reduction [301,302,303].  
 Niessner et al. [293], evaluated effect of endurance training on 
atherosclerosis inflammatory markers in subjects with CAD and 
cardiovascular risk factors (CVRFs). In this study, after an interven-
tion period of 12 weeks, authors found a significant decrease of the 
chemokines interleukin (IL)-8 (pre: 3.9±0.6, change: 1.2±0.4 
pg/ml, 21%, p = 0.002) and monocyte chemoattractant protein-1 
(pre: 213±9, change: 20.4±8.2 pg/ml, 5%, p = 0.03) and of ma-
trix metalloproteinase-9 (MMP-9), that highly significantly de-
creased in response to training (pre: 750+/-98, change: -278+/-77 
ng/ml, -18%, p=0.005), but a unsignificant change of IL-6 (pre: 
1.7+/-0.3, change: +0.25+/-0.7 pg/ml, +4%, p=0.58) and hsCRP 
(pre: 2.1+/-0.5, change: -0.25+/-0.4 mg/l, -9%, p=0.54) (see Table 
1) and [293]; rather low levels of acute phase reactants with high 
relative intraindividual variations may have limited the ability to 
find a significant change with the sample size of this cohort. 
 Kasapis et al. [304] in their paper underline the inverse rela-
tionship existing between serum CRP levels and both physical ac-
tivity level and cardiorespiratory fitness, finding out several emerg-
ing potential mechanisms to enlighten the CRP decrease induced by 
exercise training alone or as a core component of a cardiac rehabili-
tation program, all of them closely related to the decrease of cyto-
kine production, namely IL-6, IL-1, and TNF- [304]. These asso-
ciations remain after controlling for potential confounders in some 
studies [305,306,307], although other authors suggest that may be 
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influenced by factors, such as gender, body composition and the 
type of physical activity. 
 The relationship between obesity and CRP levels, was particu-
larly analyzed. The effect of physical exercise of reduction of obe-
sity, particularly central obesity, with a consequent decrease in the 
adipocyte production of inflammatory cytokines, seems infact to be 
a confounding factor for explaining CRP reduction levels after 
physical exercise. It is well documented that obesity, especially 
central obesity, is associated with CRP levels [305,306], possibly 
due to the increased production of the inflammatory cytokines IL-6 
and TNF-, by the adipocyte [308]. Accordingly, exercise could 
mitigate inflammation by reducing body weight.  
 In NHANES III (Third National Health and Nutrition Examina-
tion Survey III [309]), jogging and aerobic dancing were associated 
with lower CRP levels when compared with other forms of activity, 
including swimming, cycling and weightlifting. In this study [309], 
involving  13,748 US adults age 20 years or older, time devoted to 
physical activity is inversely associated with CRP, fibrinogen con-
centrations, and white blood cell count. In particular, after adjusting 
for several confounding factors, the risk reduction for elevated CRP 
concentrations (dichotomized at the 85th percentile of the sex-
specific distribution) were 2%, 15%, and 47% for participants who 
engaged in light, moderate, and vigorous physical activity, respec-
tively. In another study of the Third National Health and Nutrition 
Examination Survey, Abramson and Vaccarino [310] reported that 
of 3638 healthy US men and women age 40 years and older studied, 
a graded reduction in elevated CRP levels resulted from the number 
of times the participants engaged in physical exercise. The reduc-
tion in the risk of those engaging in physical activity 4-21 times per 
month was 23%, while the reduction of those engaging 22 or more 
times per month was 47%. Similar associations were seen for white 
blood cell count and fibrinogen levels.  
 Several observational studies indicate that chronic physical 
activity reduces CRP levels more in males than females [311,312], 
and no relationship between physical activity levels and CRP is 
found in some studies after adjusting for BMI (body mass index) 
and other risk factors [313,314]. However, exercise training de-
creased the circulating levels of Il-6, Il-1, and CRP levels by 48% 
independent of changes in body weight or body mass index [289]. 
Likewise, exercise training also reduced the levels of CRP in CAD 
patients who experience weight gain [297] or who experienced no 
changes in body fat [295], suggesting that other factors could con-
tribute to the exercise-related anti-inflammatory effect. The de-
creased production of cytokines in others sites beyond adipose tis-
sue, such as skeletal muscle and mononuclear cells could be pointed 
out as another possible mechanism mediating the anti-inflammatory 
effect of exercise. 
 A meta-analysis of RCTs (randomized controlled clinical trials) 
published recently concluded that aerobic exercise training does not 
reduce basal CRP levels [315]. This meta-analysis included data 
from 323 subjects in five separate trials in which subjects were 
randomized to either a control group or an aerobic exercise inter-
vention lasting at least 8 weeks. Overall, there was a 3% reduction 
in CRP levels in the exercise groups, but this change was not statis-
tically significant.  
 An interesting work by Kohut et al. [316], not reported in the 
previously cited meta-analysis, being published afterwards, com-
pared effects of aerobic exercise treatment and flexibility/strength 
exercise treatment performed 3 days/week, 45 min/day for 10 
months. Authors found that aerobic exercise, but not flexibility and 
resistance exercise, significantly reduced serum CRP, L-6, and IL-
18 compared to the strength/flexibility treatment (significant treat-
ment x time interaction, p<.05), whereas TNF-alpha declined in 
both groups (main effect of time, p=.001) [316]. 
 In a recent paper by Plaisance and Grandjean [317], the authors 
reviewed data from a number of longitudinal studies and concluded 
that long-term exercise training significantly reduces CRP levels, 
and that this effect may be independent of baseline CRP levels, 
body composition and weight loss. However, none of the studies 
reviewed were RCTs. In the only study with a control group, CRP 
was reduced from 1.19 to 0.82 mg/l (31%) in highly trained runners 
after 9 months of increased training in preparation for a marathon, 
but did not change significantly in non-training control subjects 
[318]. Although the reduction in CRP in the training group in this 
study was statistically significant, the physiological relevance of 
such a small absolute change in CRP levels is unknown. Further-
more, because the subjects in the ‘training’ group were already 
highly fit runners, the significance of these findings to the popula-
tion at large is also uncertain. 
 Additional RCTs assessing the effects of exercise training on 
CRP levels are clearly needed. Most of the studies conducted to 
date have included interventions of 4 months or less, many have 
included subjects with relatively low baseline CRP levels and al-
most none have not controlled for statin use. In addition, it is uncer-
tain whether exercise has a direct effect on CRP levels independent 
of weight loss. Weight loss has consistently been shown to reduce 
CRP levels [319]. Most exercise training interventions have shown 
modest or no effects on CRP after statistically correcting for weight 
loss, but few studies have assessed the effect of different types of 
exercise on CRP in the absence of weight loss [319,320,321]. 
Longer-term studies controlling for these factors are needed before 
any significant conclusions can be drawn regarding the impact of 
regular exercise on serum CRP levels. Probably on of the longer 
study available is the DNASCO (DNA Polymorphism and Carotid 
Atherosclerosis) Study [322], a 6-year randomized, controlled trial 
in a population-based sample of middle-aged men, we investigated 
the effect of regular long-term physical exercise on chronic low-
grade inflammation and the progression of atherosclerosis. In this 
study High-sensitivity CRP levels were statistically nonsignifi-
cantly lower in the exercise group than in the control group after 6 
years of aerobic training, and also the progression of intima-media 
thickness in the carotid artery did not differ between the study 
groups (P > 0.2). The study was probably underpowered to detect 
changes in high-sensitivity CRP level, confirming how in future 
larger studies, sex, age, dose response, and exercise methods should 
be addressed, to study for longer periods the interactions of regular 
exercise and atherosclerotic inflammation markers. 
 Geffken et al. [323], reported consistent findings in the Cardio-
vascular Health Study cohort of 5888 men and women. Compared 
with those in the lowest quartile of self-reported physical activity, 
those in the highest quartile had 19%, 6%, 4%, and 3% lower con-
centrations of CRP, white blood cells, fibrinogen, and factor VIII 
activity, respectively, after adjustment for gender, presence of 
CVD, age, race, smoking, body mass index (BMI), diabetes, and 
hypertension. It was also suggested by the same investigators [323] 
that the association of higher levels of physical activity with lower 
levels of inflammation markers may be mediated by BMI and glu-
cose. Further support for the latter hypothesis is provided by a re-
port on the association between BMI and CRP, IL-6, and soluble 
tumor necrosis factor receptors (sTNF-Rs) 1 and 2. [324], Further 
biomarkers were measured in 405 healthy men and 454 healthy 
women from two large ongoing prospective studies. 
 After adjustment for other predictors of inflammation, physical 
activity was inversely associated with plasma levels of sTNF-R1, 
sTNF-R2, IL-6, and CRP (p=0.07, p=0.004, p=0.04, and p=0.009, 
respectively). After further adjustment for BMI and leptin, most of 
these associations were insignificant surrogates for fat mass [324]. 
 These study confirm the previous data reported in which has 
been addressed the hypothesis that obesity not only can interfere 
with achieving the level of physical activity necessary for cardio-
vascular health but also, therefore, could represent an independent 
factor affecting inflammatory markers and interfering with physical 
activity. Other interference between adipokynes, myokines, cardio-
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vascular and systemic effects of chronic exercise and inflammatory 
markers of atherosclerosis cannot be excluded. 
 In a study by Reuben et al., [325], 870 persons aged 70-79 
years in the top 33% of community-dwelling older persons with 
respect to physical and cognitive functioning observed an associa-
tion between high levels of recreational activity and lower levels of 
the inflammatory markers, i.e., IL-6 and CRP. Their findings sug-
gest a mechanism for the protective effect of physical activity and 
support interventions that increase physical activity in older persons 
in order also to prevent progression of subclinical atherosclerosis . 
 Although not directly related to atherosclerosis the previously 
cited work by Mattusch et al. [318] provide further interesting data. 
The authors measured CRP serum levels before and after 9 months 
of training in 14 subjects preparing for a marathon, studying the 
outcome effect of training on the baseline CRP concentration. Al-
though training intensity was continuously increased, baseline CRP 
diminished in 10 of the 12 runners. The CRP median fell from 1.19 
mg/L before training to 0.82 mg/L after training (p<0.05). Since we 
stressed the concept of paradox pro-inflammatory effects of acute 
intense physical activity, it is interesting report that after strenuous 
repeated aerobic exercise bouts the CRP basal levels decreased. The 
decrease of CRP concentration after intense regular training sug-
gests that also intensive regular exercise has a systemic anti-
inflammatory effect, contrary to the effect on muscles and tendons. 
These informations should probably be usefully assimilated in pro-
tocols dedicated to cardiologic rehabilitation, testing stronger exer-
cise protocols in order to evaluate if can be reached more ambitious 
reduction target of the inflammatory markers. 
 The various experimental models only partly justify the hetero-
geneous results showed before; certainly different types of training 
interventions are obvious reasons for discrepancies, e.g., endurance 
training versus resistance training; differences in the intensity of 
exercise and/or time duration of the single bout of exercise, as well 
as the full duration of the intervention program. Discrepancies may 
be found not only in the trials that have addressed the issue regard-
ing the potentiality of regular exercise training to reduce serum 
CRP level, but also studies examining the effects of chronic exer-
cise on cytokine production and circulating cytokine levels have 
been somewhat conflicting.  
 Cross-sectional studies indicate that increasing levels of physi-
cal activity and/or fitness are generally associated with modest re-
ductions in circulating levels of TNF- and IL-6, and increased 
levels of IL-10 [53,289,293]. Consistent with this, Smith et al. 
[294] observed a 58% reduction in the production of the proin-
flammatory cytokines IFN- (interferon-), TNF- and IL-1, and a 
36% increase in the production of the anti-inflammatory cytokines 
TGF- (transforming growth factor- ), IL-4 and IL-10, by cultured 
mononuclear cells from individuals at risk of developing ischemic 
heart disease following 6 months of exercise training compared 
with baseline levels. In addition, some studies demonstrate reduced 
circulating levels of TNF-, IL-6, IFN- and other markers of sys-
temic inflammation following exercise training, although several 
others do not (reviewed in [294]). These changes in cellular func-
tion were reflected in the serum levels of CRP, which decreased by 
35%, although without reaching statistical significance. These dis-
crepancies may be due to a number of factors, including differences 
in subject characteristics, the type and intensity of the exercise in-
tervention, the timing of the blood samples taken and inherent vari-
ability in the assays used to measure many of these cytokines. Nev-
ertheless, the preponderance of evidence suggests that both acute 
and chronic exercise is associated with modest improvements in 
markers of systemic low-grade inflammation. 
 Also in patients with heart failure, six months of exercise train-
ing reduced the skeletal muscle TNF-, IL-1-beta and Il-6 expres-
sion. However the serum levels of the above mentioned parameters 
remained unaffected [138], raising the question of whether this 
local change has physiological repercussions at a systemic level. 
The enhancement of endothelial function could be another option to 
justify the decrease of inflammatory status by exercise training, 
through the reduction of IL-1 and IL-6 released by the endothelium. 
In fact, several studies have provided evidence supporting the posi-
tive impact of exercise training on endothelial function; as earlier 
explained, exercise training improves ˙NO bioavailability [267] and 
reduces circulating markers associated with endothelial dysfunction 
[284,285]. Finally, the favourable impact of exercise training on 
biomarkers of inflammation could be related to the diminishment of 
oxidative stress and LDL oxidation, hence reducing monocyte acti-
vation and, in this way, attenuating the production of inflammatory 
cytokines. Indeed, exercise training reduces oxidative stress in 
skeletal muscle [327] and in the vasculature [268], and reduces the 
level of circulating markers of oxidative stress [328]. 
 As previously underlined, TNF- levels don not increase after 
acute exercise [51,53]. Effects of chronic exercise on basal TNF- 
levels have been evaluated by Starkie et al. [73], performed three 
experiments in which healthy young men rested for 3 h (control), 
rode a bicycle for 3 h, and were infused with rIL-6 for 3 h. After 
21/2 h, subjects received a bolus of Escherichia coli endotoxin in all 
experiments. This resulted in a twofold increase in circulating TNF-
 in the control experiment, whereas the response was totally at-
tenuated in relation to exercise or rIL-6 administration. This ex-
periment supports the hypothesis that physical activity mediates 
strong anti-inflammatory effects also against this main pro-
inflammatory cytokine; an effect reasonable mediated by the mus-
cular production of IL-6 and the other anti-inflammatory myokines 
able to interfere with immunologic asset of the organism, as under-
lined before in this paper. Nevertheless of this, a modest decrease in 
TNF- was also observed in IL-6 KO mice, suggesting the exis-
tence of anti-inflammatory exercise effects mediated via IL-6 and 
an IL-6-independent mechanism [329]. In accordance with experi-
mental observations, TNF- mRNA in skeletal muscle declined in 
relation to a training intervention in patients with chronic heart 
failure, whereas a decline in systemic low-level inflammation was 
not detected [138]. 
 However, TNF- mRNA was not reduced in skeletal muscle 
after 8 weeks of bicycle exercise in obese adults [330]. 
CONCLUSIONS 
 Atherosclerosis, and, in particular, its acute complications, is a 
major cause of mortality and morbidity around the world and is 
likely to continue to increase as a cause of death. Prevention and 
treatment of cardiovascular disease is still a clinical challenge. Sev-
eral lines of research have converged to suggest that the biology of 
the plaque is the real ‘culprit’ of clinical manifestations of athero-
sclerosis. 
 Inflammatory signaling pathways are implicated in early 
atherogenesis, in the progression of lesions and finally in the acute 
complications of the disease. The recent identification of skeletal 
muscle as an endocrine organ that produces and releases myokines 
expands our knowledge on how the nervous, endocrine, and im-
mune systems contribute to the maintenance of homeostasis, espe-
cially when energy demands are increased. Since in the 1990s the 
discovery of adipose tissue as a secretory organ dominate the re-
searchs in this area, the finding that muscles produce and release 
cytokines (myokines) suggests that in addition to adipose tissue 
working skeletal muscle may be a major source of secreted mole-
cules.  
 Myokines may be involved in mediating the health beneficial 
effects of exercise and play important roles in the protection against 
diseases associated with chronic low-grade inflammation, such as 
insulin resistance, type 2 diabetes, cancer and, naturally, cardiovas-
cular atherosclerotic disease. Given that atherosclerotic process is 
characterized in all its phases by inflammation, many theoretical 
benefits could be provided by regular exercise, although further 
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scientific validations about the improvement on atherosclerosis 
progression, about the outcome benefit of atherosclerotic patient 
and finally about regression of low-grade inflammation and rela-
tionship between myokines and systemic inflammatory mediators 
of atherosclerosis are needed. 
 It is obvious that knowledge about the mechanisms whereby 
regular exercise offers protection against chronic diseases in com-
bination with clinical research serves as a foundation for the devel-
opment of public health guidelines with regard to exercise. Moreo-
ver, more specific knowledge about the mechanisms whereby exer-
cise alters the function and metabolism in other organs, such as 
adipose tissue, liver, and brain, is required to prescribe exercise as 
therapy in the form of endurance training, metabolic training, or 
strength conditioning, since different types of exercise provide dif-
ferent degree of variations of systemic inflammation through differ-
ent myokinic muscular response. 
 Finally, it is obvious that the identification of new myokines 
and their receptors will potentially serve as pharmacological targets 
for the prevention and treatment of atherosclerotic disease, meta-
bolic disorders and other chronic diseases. 
 Nevertheless discrepancies, analysis of available researches 
seem to confirm the efficacy of regular physical training as a non-
pharmacological therapy having target chronic low-grade inflam-
mation. Given this, physical exercise could be considerate a useful 
weapon against local vascular and systemic inflammation in athero-
sclerosis. Several mechanisms explain the positive effect of chronic 
exercise, nevertheless, these mechanisms do not fully enlighten all 
pathways by which exercise can decrease inflammation and endo-
thelial dysfunction, and hence modulate the progression of the un-
derlying disease progress. Future research is needed to provide 
convincing support to the mechanisms explaining the beneficial 
effect of exercise in the inflammatory profile of atherosclerotic 
patients. 
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